

1

## 2 Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies 3 that maintain potency against B.1.617

4

5 Lei Peng <sup>1,2,3,\*</sup>, Yingxia Hu <sup>4,\*</sup>, Madeleine C. Mankowski <sup>5,6,\*</sup>, Ping Ren <sup>1,2,3,\*</sup>, Rita E. Chen <sup>18</sup>,  
6 Jin Wei <sup>5,6</sup>, Min Zhao <sup>7</sup>, Tongqing Li <sup>8,9</sup>, Therese Tripler <sup>4</sup>, Lupeng Ye <sup>1,2,3</sup>,  
7 Ryan D. Chow <sup>1,2,3,10,11</sup>, Zhenhao Fang <sup>1,2,3</sup>, Chunxiang Wu <sup>4</sup>, Matthew B. Dong <sup>1,2,3,6,10,12</sup>,  
8 Matthew Cook <sup>4</sup>, Guilin Wang <sup>13</sup>, Paul Clark <sup>1,2,3</sup>,  
9 Bryce Nelson <sup>8,9</sup>, Daryl Klein <sup>8,9</sup>, Richard Sutton <sup>7</sup>,  
10 Michael S. Diamond <sup>18,19</sup>, Craig B. Wilen <sup>5,6,@</sup>, Yong Xiong <sup>4,@</sup> and Sidi Chen <sup>1,2,3,11,12,14,15,16,17,@,#</sup>

11

12

### 13 Affiliations

14

- 15 1. Department of Genetics, Yale University School of Medicine, New Haven, CT, USA
- 16 2. System Biology Institute, Yale University, West Haven, CT, USA
- 17 3. Center for Cancer Systems Biology, Yale University, West Haven, CT, USA
- 18 4. Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA
- 19 5. Department of Laboratory Medicine, Yale University, New Haven, CT, USA
- 20 6. Department of Immunobiology, Yale University, New Haven, CT, USA
- 21 7. Section of Infectious Diseases, Department of Internal Medicine, Yale University, New Haven, CT, USA
- 22 8. Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA
- 23 9. Cancer Biology Institute, Yale University, West Haven, CT, USA
- 24 10. M.D.-Ph.D. Program, Yale University, West Haven, CT, USA
- 25 11. Molecular Cell Biology, Genetics, and Development Program, Yale University, New Haven, CT, USA
- 26 12. Immunobiology Program, Yale University, New Haven, CT, USA
- 27 13. Yale Center for Genome Analysis, Yale University, New Haven, CT, USA
- 28 14. Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA
- 29 15. Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, USA
- 30 16. Yale Stem Cell Center, Yale University School of Medicine, New Haven, CT, USA
- 31 17. Yale Center for Biomedical Data Science, Yale University School of Medicine, New Haven, CT, USA
- 32 18. Departments of Medicine and Pathology & Immunology, Washington University School of Medicine in St. Louis,  
33 St. Louis, MO, USA
- 34 19. Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO,  
35 USA

36

37

38

39 \* Co-first authors. Contributed equally.

40

41 @ Correspondence:

42 Craig B. Wilen ([craig.wilen@yale.edu](mailto:craig.wilen@yale.edu)), Yong Xiong ([yong.xiong@yale.edu](mailto:yong.xiong@yale.edu)) and Sidi Chen ([sidi.chen@yale.edu](mailto:sidi.chen@yale.edu))

43

44 # Lead contact:

45 SC ([sidi.chen@yale.edu](mailto:sidi.chen@yale.edu))  
46 +1-203-737-3825 (office)  
47 +1-203-737-4952 (lab)

48

49

1 **Abstract**

2 COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million deaths to date.  
3 Although multiple vaccines are available, breakthrough infections occur especially by emerging variants.  
4 Effective therapeutic options such as monoclonal antibodies (mAbs) are still critical. Here, we report the  
5 development, cryo-EM structures, and functional analyses of mAbs that potently neutralize SARS-CoV-2  
6 variants of concern. By high-throughput single cell sequencing of B cells from spike receptor binding domain  
7 (RBD) immunized animals, we identified two highly potent SARS-CoV-2 neutralizing mAb clones that have  
8 single-digit nanomolar affinity and low-picomolar avidity, and generated a bispecific antibody. Lead  
9 antibodies showed strong inhibitory activity against historical SARS-CoV-2 and several emerging variants of  
10 concern. We solved several cryo-EM structures at ~3 Å resolution of these neutralizing antibodies in complex  
11 with prefusion spike trimer ectodomain, and revealed distinct epitopes, binding patterns, and conformations.  
12 The lead clones also showed potent efficacy *in vivo* against authentic SARS-CoV-2 in both prophylactic and  
13 therapeutic settings. We also generated and characterized a humanized antibody to facilitate translation and  
14 drug development. The humanized clone also has strong potency against both the original virus and the  
15 B.1.617.2 Delta variant. These mAbs expand the repertoire of therapeutics against SARS-CoV-2 and emerging  
16 variants.  
17  
18

1

## 2 Introduction

3 In the ongoing coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome  
4 coronavirus (SARS-CoV-2) has infected over 270 million individuals, resulting in more than 5 millions of  
5 deaths around the globe <sup>1</sup>. Although multiple vaccines are available, breakthrough infections still occur <sup>2</sup>,  
6 especially with variant strains. Thus, broadly effective therapeutic options are critical for medical treatment.  
7 Monoclonal antibodies (mAbs) have been effectively deployed for prevention or treatment of COVID-19 <sup>3</sup>.  
8 However, the emergence of mutations in spike <sup>4</sup> and new variant lineages calls for developing additional  
9 therapeutic interventions, including mAbs with potent and broadly neutralizing ability.

10

11 Certain variants affect the rate of spread and/or even the ability to evade immune recognition, potentially  
12 dampening the efficacy of antibody therapy or vaccines and have been designated by WHO and CDC as  
13 “variants of concern” (VoC) <sup>3</sup>. The B.1.1.7 lineage (Alpha variant) has an increased rate of transmission and  
14 higher mortality <sup>5</sup>. The B.1.351 lineage (Beta variant) has an increased rate of transmission, resistance to  
15 antibody therapeutics, and reduced vaccine efficacy <sup>6-8</sup>. The lineage B.1.617 including B.1.617.1 (Kappa  
16 variant), B.1.617.2 (Delta variant) and B.1.617.3 have emerged and became dominant in multiple regions in  
17 the world <sup>9,10</sup>. The B.1.617 lineage has an increased rate of transmission, shows reduced serum antibody  
18 reactivity in vaccinated individuals, and exhibits resistance to antibody therapeutics under emergency use  
19 authorization (EUA) <sup>11-15</sup>. The Delta variant has become dominant in US and many countries across the globe  
20 <sup>16-18</sup>. A newly emerged variant Omicron (B.1.1.529) with extensive mutations in the Spike gene also shows  
21 rapid transmission <sup>19-21</sup>. With these VoCs, even emergency-use authorized (EUA) mAb therapies have face  
22 challenges with resistant viral variants, causing some to be withdrawn, highlighting a need for more mAb  
23 candidates in development. Discovery of neutralizing antibodies with broad neutralizing activities or multi-  
24 specific antibodies, which can increase antibody efficacy and prevent viral escape, might improve the  
25 countermeasure arsenal against COVID-19 <sup>3</sup>.

26

27 The majority of pre-clinical and clinical SARS-CoV-2 mAbs were discovered utilizing the blood of COVID-  
28 19 patients <sup>3</sup>. In comparison, immunization of mice followed by hybridoma screening is a standard method for  
29 discovering of therapeutic mAbs against viruses<sup>22</sup>. However, hybridoma screening for potent neutralizing  
30 mAbs from immunized mice is a slow and laborious process. The recent development of high-throughput  
31 single-cell technologies enabled direct sequencing of fully recombined VDJ sequences of B cell receptor (BCR)  
32 repertoires from single cells <sup>23,24</sup>. This technology has successfully been used to isolate human neutralizing  
33 mAbs against pathogens such as HIV, Ebola viruses, and recently SARS-CoV-2 <sup>25,26,27-29</sup>.

1  
2 The SARS-CoV-2 surface spike glycoprotein (S) mediates entry into target cells and is a primary target of  
3 neutralizing antibodies<sup>30-32</sup>. SARS-CoV-2 spike is a trimer in the prefusion form, consisting of three copies of  
4 S1 and S2 subunits<sup>33,34</sup>. The S1 subunit is composed of an N-terminal domain (NTD) and a C-terminal receptor  
5 binding domain (RBD) that recognizes the host angiotensin-converting enzyme 2 (ACE2) receptor on the cell  
6 surface<sup>31,35-37</sup>. The S2 subunit contains the fusion peptide, along with other key regions, to induce membrane  
7 fusion of the virus and the target cell<sup>38</sup>. Spike RBD is flexible, moving between “up” and “down”  
8 conformations but only binds to ACE2 in the up conformation<sup>34,36,39</sup>. Previous studies have suggested that  
9 most of the potent SARS-CoV-2 neutralizing antibodies target spike RBD through an interface directly  
10 overlapping with the ACE2-binding surface<sup>40,41</sup>.

11  
12 Here, we report the rapid identification of highly potent SARS-CoV-2-neutralizing mAbs using high-  
13 throughput single-cell BCR sequencing from mice immunized with purified SARS-CoV-2 RBD. We generated  
14 a bispecific antibody with two antigen-recognition variable regions from two of the top mAb clones against  
15 SARS-CoV-2 RBD. These monospecific and bispecific antibodies displayed high affinity and avidity to the  
16 RBD antigen, and potently neutralized historical and B.1.617 lineage viruses. We also generated and  
17 characterized a humanized antibody to facilitate clinical development, and showed strong potency against both  
18 the original virus and the Delta variant, both *in vitro* and *in vivo*. We resolved the three-dimensional cryo-EM  
19 structures of these neutralizing antibodies in complex with the spike-ectodomain trimer, which showed the  
20 epitopes as well as the combinations of open and close RBD conformations of trimeric spike bounded to the  
21 mAbs. Structure-based mutation and epitope analysis revealed the neutralization potency of the lead mAb  
22 clones against B.1.617 variants.

23

## 24 **Results**

### 25 **Single cell BCR sequencing of RBD-immunized mice identified enriched BCRs encoding strong mAbs 26 against SARS-CoV-2**

27 To generate potent and specific mAbs against SARS-CoV-2, we immunized two different mouse strains:  
28 C57BL/6J and BALB/c with RBD protein with a C-terminal hexahistidine tag following a standard 28-day  
29 immunized protocol (**Extended Data Fig. 1a**). Using anti-mouse CD138 beads, we isolated progenitor B cells  
30 and plasma B cells from spleen, lymph node, and bone marrow of selected immunized mice that showed high  
31 serum binding titers against RBD (**Extended Data Fig. 1a**). We performed single cell VDJ (scVDJ)  
32 sequencing on the isolated B cells (**Extended Data Fig. 1a**). The scVDJ data revealed the landscape of  
33 immunoglobulin clonotypes in immunized mice (**Fig. 1a; Dataset S1**), and identified enriched IgG1 clones

1 **(Fig. 1b and Dataset S1).** We took the VDJ sequences 11 top-ranked IgG1+ clones by clonal frequency. We  
2 then cloned the paired variable region of heavy and light chain into human IgG1 (hIgG1) heavy and light chain  
3 backbone vectors separately, for antibody reconstruction utilizing the Expi293F mammalian expression system.  
4

5 **Anti-Spike RBD monoclonal antibodies have single-digit nanomolar affinity and low-picomolar avidity**

6 After expression and purification of hIgG1 antibody clones, we tested their reactivity against SARS-CoV-2  
7 spike RBD by ELISA. Eight of the eleven mAbs showed positive RBD-binding (**Extended Data Fig. 1c**). We  
8 then screened mAb clones showing high RBD ELISA positive rate for their neutralizing ability using an HIV-  
9 1-based SARS-CoV-2 pseudovirus system and a VSV-based SARS-CoV-2 pseudovirus system (**Extended**  
10 **Data Fig. 2a-c**). Two mAbs, Clones 2 and 6, showed strongest binding and neutralizing activity (**Extended**  
11 **Data Fig. 2a-c**). As SARS-CoV-2 continues to mutate and evolve, leading to variants, it is critical to prevent  
12 viral escape from antibody recognition. To overcome this problem, antibody combinations from two or more  
13 mAbs have been developed and utilized<sup>42</sup>. As an alternative, a single bispecific mAb can be used, as it can  
14 recognize two epitopes. One advantage of bispecific mAbs is that a single antibody product can be  
15 manufactured instead of two separate mAbs, which in theory could reduce the cost and formulation complexity.  
16 Thus, we generated a bispecific antibody using the antigen-specific variable regions of both Clones 2 and 6  
17 (named as Clone 16). To generate the bispecific antibody, we utilized (i) a “knobs into holes” (KiH)  
18 methodology, and (ii) a CrossMAb-KiH bispecific backbone, to ensure the correct heterodimerization of the  
19 two different heavy chains, and (iii) a CH1 and CL exchange in heavy and light chain of one-half IgG to ensure  
20 correct pairing of heavy and light chains of each variable region (**Extended Data Fig. 1d**). We validated the  
21 antigen-specificity of the bispecific antibody along with its two parent mAbs using ELISA (**Extended Data**  
22 **Fig. 1e**).  
23

24 To characterize the biophysical nature of the RBD reactivity of lead clones, we performed biolayer  
25 interferometry (BLI) and surface plasmon resonance (SPR) (**Fig. 1c-e**). BLI results showed that Clones 2 and  
26 6 bound to the RBD with picomolar level dissociation constant (Kd) (**Fig. 1f**). The binding is particularly  
27 strong so that the dissociation stage was never observed in the BLI assay (**Fig. 1c**). SPR using an NTA-CHIP  
28 based assay with the RBD-antigen immobilized also revealed picomolar level dissociation constant (Kd) for  
29 Clones 2 and 6 (**Fig. 1d**). In the NTA-CHIP, where the RBD-antigen is immobilized, multiple binding events  
30 can occur, leading to potential trimer formation of RBD protein and measurement of avidity. In parallel, we  
31 performed SPR with an Fc-CHIP based assay with pre-coated antibodies, which measures monovalent binding  
32 between RBD and the antibody. Results from Fc-CHIP SPR assay revealed strong affinity with single-digit  
33 nanomolar Kd of Clone 2 and Clone 6 (**Fig. 1e**). A humanized Clone 2 (named Clone 13) maintained strong

## SARS-CoV-2 mAbs and CryoEM structures

1 binding affinity to RBD at low-double-digit nanomolar Kd (**Fig. 1e**). The bispecific Clone 16 also displayed  
2 high affinity to RBD also at single-digit nanomolar Kd (**Fig. 1e**), although not significantly higher than either  
3 parental clone alone.

4

### 5 **Cryo-EM structures of lead antibody clones bound to the SARS-CoV-2 spike define epitopes and** 6 **binding conformations**

7 We then generated Fab fragments of the lead clones and determined the cryo-EM structures of Clone 2 or 6  
8 Fabs in complex with the ectodomain of SARS-CoV-2 spike trimer (S trimer) at ~3 Å resolution (**Table 1**). In  
9 both cases, a S trimer is bound with three Fab molecules, one per RBD in various conformations. In total, we  
10 determined five different Fab-S trimer complex structures, each with the S trimer in a specific conformational  
11 state. Clone 2 Fab binds to S trimer in two states, one with 2 RBDs in the up conformation (60% of all  
12 complexes) and one with all 3 RBDs up (40%) (**Fig. 2a; Extended Data Fig. 3a**). Clone 6 Fab binds to S  
13 trimer in three states, one with all 3 RBDs down (26% of all complexes), one with 1 RBD up (43%) and one  
14 with 2 RBDs up (31%) (**Fig. 2b; Extended Data Fig. 3b**). Thus, Clones 2 and 6 Fab molecules are capable of  
15 recognizing SARS-CoV-2 S trimer in all possible RBD conformations, potentially reducing viral immune  
16 evasion when used in combination or as a bi-specific. Within each clone, the same Fab-RBD binding interface  
17 is maintained regardless of the RBD conformations across all S trimer states. Between the two clones, the Fab-  
18 RBD interfaces are different, although the two Fab clones bind RBD in similar locations with RBD adopting  
19 virtually the same conformation (RMSD 0.46 Å) (**Fig. 3a,b**). Clone 2 Fab-S trimer complexes appear more  
20 flexible than Clone 6 complexes, as indicated by less well-defined cryo-EM density in the Clone 2 Fab-RBD  
21 regions.

22

23 Besides the major Fab-RBD interfaces described above, in the Clone 6 Fab complexes with 2 or 3 RBDs down,  
24 a down-RBD-binding Fab makes an additional contact to a side surface of an adjacent down-RBD to lock both  
25 RBDs in the closed conformation incompetent in ACE2 recognition (**Extended Data Fig. 4d left two panels**),  
26 which may provide a second neutralization mechanism. The additional contact is achieved by the CDRL1 loop  
27 of Clone 6 Fab that protrudes in between the two neighboring down-RBDs (**Extended Data Fig. 4c**), along  
28 with the framework region 3 (FWR3) of the Fab that interacts a nearby side surface of the adjacent down-RBD  
29 (**Extended Data Fig. 4d, left two panels**). In addition, in all complexes with 2 up/1 down-RBDs and the Clone  
30 6 Fab complex with 2 down/1 up-RBDs, a down-RBD-binding Fab contacts the side surface of an adjacent  
31 up-RBD through another conserved interface mainly involving the CDRL1 loop of the Fabs (**Extended Data**  
32 **Fig. 4b; Extended Data Fig. 4d, right panels**), further stabilizing the conformation of the adjacent up-RBDs.  
33 These types of bivalent interactions are not observed for the up-RBD-binding Fabs.

1  
2 Clone 2 and Clone 6 Fabs interact with spike RBD at similar locations, as both directly block access of the  
3 host receptor ACE2 (**Fig. 3a**). Clone 6 Fab shields the entire top surface of spike RBD (both “left shoulders”  
4 and “right ridge”), whereas Clone 2 Fab has a relative rotation of  $\sim 17^\circ$  pivoted on the RBD right ridge, resulting  
5 in a larger contact area there and less contact with the RBD left shoulder (**Fig. 3b**). When overlaying a Clone  
6 2 Fab-bound down-RBD onto a Clone 6 Fab-bound down-RBD in the S trimer with more than one RBDs  
7 down, spatial clashes are detected between the Clone 2 Fab and the neighboring down RBD (**Extended Data**  
8 **Fig. 4a**). This also explains why we did not observe Clone 2 Fab-bound S trimer in a conformation state with  
9 more than one RBD down. In each case, all six complementarity determining regions (CDRs) of the Fab  
10 participate in RBD interactions (**Fig. 3c**). The 3 CDRH loops of the two clones share similar overall  
11 conformations and interact mainly with the right ridge of spike RBD (**Fig. 3c, upper panel**). The 3 CDRH  
12 loops of Clone 2 Fab form a large positively charged paratope, complementing a negatively charged epitope  
13 contributed by the right ridge of spike RBD (**Extended Data Fig. 5a**, upper panels). The 3 CDRH loops of  
14 Clone 6 Fab engage spike RBD predominantly through hydrophobic interactions (**Extended Data Fig. 5b**,  
15 upper left), with the CDRH3 loop also engaging RBD through modest electrostatic interactions (**Extended**  
16 **Data Fig. 5b**, upper right).  
17

18 In contrast to the relatively conserved binding locations by the CDRH loops, the 3 CDRL loops of Clones 2  
19 and 6 diverge in RBD-binding paratopes (**Fig. 3c, lower panel**). CDRL1 and CDRL3 of Clone 2 Fab primarily  
20 contact the epitopes at RBD right ridge and the CDRL2 loop engages RBD central groove, whereas CDRL3,  
21 CDRL1 and CDRL2 of Clone 6 Fab complement with the RBD right ridge, central groove and left shoulder,  
22 respectively, together covering the top surface of the RBD. Both Clones 2 and 6 Fab CDRL loops contact spike  
23 RBD primarily through hydrophobic interactions along with modest electrostatic interactions (**Extended Data**  
24 **Fig. 4b and 5a**, lower panels). A comparison of the Clone 2 and Clone 6 Fabs revealed that the most different  
25 region comes from the CDRH3 loop (**Fig. 3d**). The Clone 6 Fab contains a longer CDRH3 loop, which inserts  
26 into the central groove of spike RBD to generate a tighter engagement. As a consequence, this induces a  
27 substantial change in the RBD, which otherwise maintained a nearly identical conformation, where residue  
28 F486 flips to contact the CDRL3 loop of Clone 6 instead of interacting with the CDRH3 loop of Clone 2 (**Fig.**  
29 **3d**). Even though the two Fabs interact with the RBD with similar buried surface areas ( $949 \text{ \AA}^2$  in Clone 2 vs.  
30  $894 \text{ \AA}^2$  in Clone 6), the further spread-out RBD-binding mode of Clone 6 Fab is more similar to that of host  
31 ACE2 receptor (**Fig. 3e**).  
32

## SARS-CoV-2 mAbs and CryoEM structures

1 Multiple mAbs have been generated to date and are in various stages of research and development, with some  
2 granted EUA for clinical use<sup>3,28,43-45</sup>. We compared our structures to several of the previously published  
3 mAb:Spike structures, and found that the RBD-binding modes of Clone 2 and Clone 6 Fabs differ from these  
4 SARS-CoV-2 neutralizing antibodies reported in primary literature and the protein databank (PDB). Three  
5 previously reported antibodies (2H2, CV05-163, and S2H13) target the spike RBD in somewhat similar  
6 orientations but with substantial rotations or shifts<sup>46-48</sup> (**Extended Data Fig. 6a**). Another two reported  
7 antibodies (CT-P59 and BD23) adopt RBD-binding conformations resembling those of Clone 2 and 6 Fabs  
8<sup>49,50</sup>; however, the binding positions of heavy chains and light chains are exchanged (**Extended Data Fig. 6b**).  
9

### 10 Lead antibody clones potently neutralize SARS-CoV-2 WA1 and B.1.617 variant

11 We next tested the neutralization ability of the monospecific and bispecific clones. Because spike protein can  
12 mediate receptor-mediated membrane fusion<sup>51</sup>, we utilized a cell fusion assay in which expression of Wuhan-  
13 1/WA1 SARS-CoV-2 spike on one cell can induce fusion with hACE2-expressing cells. All three antibodies  
14 (Clone 2, Clone 6 and Clone 16) effectively inhibited this spike mediated cell fusion activity (**Extended Data**  
15 **Fig. 2d-e**). Next, we used HIV-1-based pseudovirus system pseudotyped with SARS-CoV-2 Wuhan-1/WA1,  
16 B.1.351 and B.1.617 to evaluate neutralization potential of these mAbs. All three antibodies (Clone 2, Clone  
17 6 and Clone 16) potently inhibited SARS-CoV-2-Wuhan-1 pseudovirus with low ng/mL level IC<sub>50</sub> values (**Fig.**  
18 **4a**). Due to the partial overlap in the binding domains in RBD, the bi-specific clone 16 was not stronger than  
19 either Clone 2 or Clone 6. These three antibodies also inhibited B.1.351 SARS-CoV-2 pseudovirus, with  
20 somewhat reduced potency (higher level of IC<sub>50</sub> values, mid ng/mL for Clones 2 / 6, and high ng/mL for Clone  
21 16) (**Fig. 4b**). In comparison, all three antibodies maintained potent neutralizing activity against the B.1.617  
22 pseudovirus, with sub-single-digit to low-single-digit ng/mL level IC<sub>50</sub> values (**Fig. 4c**). We also performed  
23 these experiments with Clones 2 and 6 as a cocktail combination (**Fig. 4d-f**). Although the combination is not  
24 superior to the single clone alone, the results again confirmed the potency of both Clones 2 and 6 as the single  
25 agents, where both clones showed strong potency against Wuhan-1/WA1 spike and B.1.617 pseudoviruses  
26 (single-digit ng/mL IC<sub>50</sub>) and slightly reduced potency against B.1.351 (**Fig. 4d-f**).  
27

### 28 Epitope and mutation analysis of the mAb:RBD structures on binding interface between the lead mAbs 29 and hotspot mutations in Beta and Delta variants

30 To evaluate the structural impacts of the RBD mutations on binding of the Beta and Delta variants, we used  
31 our Spike:mAb Cryo-EM structures and generated homology models of the two variants (**Fig. 4g**). The Beta  
32 variant encodes three mutations (K417N, E484K, and N501Y) in spike RBD. Although N501 is not located  
33 within the epitope region, the Y501 mutation may have weak interactions with the CDRL2 loop of both Fab

SARS-CoV-2 mAbs and CryoEM structures

clones (**Fig. 4g**, lower left). K417 has no contact with Clone 2 Fab, but interacts with the CDRL1 loop of Clone 6 Fab, and the K417N mutation would likely abolish this interaction (**Fig. 4g**, lower left). E484, which is located on top of the RBD right ridge, is targeted by the CDRH1 and CDRH3 loops of both Fab clones, and has a larger contact area on Clone 6 Fab (**Fig. 4g**, upper left). The Delta variant encodes an E484Q at the position, which likely results in less disruption of its interaction with the Fabs (**Fig. 4g**, upper right). The two other mutation sites, L452 and T478, are not located within the antibody-binding surface (**Fig. 4g**, right). However, the T478K mutation is located close to the interface, especially that with Clone 2 Fab, and could affect RBD recognition by both clones (**Fig. 4g**, lower right).

9

10 ***In vivo* prophylactic and therapeutic efficacy of the lead mAbs against authentic SARS-CoV-2 virus**

11 We next evaluated the potency of the lead antibodies against authentic SARS-CoV-2 (WA1/2020) infection. All three antibodies (Clone 2, Clone 6 and the bispecific Clone 16) inhibited infection of SARS-CoV-2 WA1/2020 (low-mid ng/mL level IC50s) (**Fig. 5a**). We then assessed efficacy of mAbs against SARS-CoV-2 *in vivo*, when administered as either pre-exposure prophylaxis or post-exposure therapy (**Fig. 5b**). We performed protection studies with SARS-CoV-2 using K18-hACE2 transgenic mice<sup>52-54</sup>. We challenged K18-hACE2 mice with  $2 \times 10^3$  plaque forming units (PFU) of SARS-CoV-2 WA1/2020 virus (**Fig. 5b**). The hACE2 transgenic mice were randomly divided into three group, and mice in each group were injected with 20 mg/kg of Clone 2 mAb, Clone 6 mAb, or placebo control; with treatment given as a single dose either 24 h before or 18 h after viral infection (**Fig. 5b**).

20

21 In the prophylactic setting, all (8/8, 100%) mice in the placebo group developed severe disease due to viral challenge, and most (7/8, 87.5%) of them lost substantial body weight and succumbed from the disease, with only one mouse recovering weight (**Fig. 5c-e**). In contrast, all mice receiving treatment of either Clone 2 (8/8, 100%) or Clone 6 (7/7, 100%) maintained their body weight throughout the duration of the study and survived SARS-CoV-2 infection (**Fig. 5c-e**). In the therapeutic setting, all (5/5, 100%) mice in the placebo group developed severe disease, and most (4/5, 80%) of them lost body weight (**Fig. 5f-h**). In contrast, all mice treated with Clone 2 (5/5, 100%) or Clone 6 (5/5, 100%) at + 18 h maintained their body weight and survived the viral infection with no signs of disease (**Fig. 5f-h**). These data suggested that these mAbs can protect the animals from lethal SARS-CoV-2 infection in either prophylactic or therapeutic settings.

29

31 **Generation, biophysical characterization, and functional testing of a humanized mAb clone**

32 To improve clinical translatability, we also developed a humanized Clone 2, using standard antibody 33 humanization approaches with framework humanization and engineered mutations, based on canonical human

SARS-CoV-2 mAbs and CryoEM structures

1 antibody backbone sequences as well as the antibody : RBD CryoEM structures (Methods). A resultant  
2 humanized clone that maintains RBD specificity was generated (Clone 13A) (**Fig. 6a**). We purified Clone 13A  
3 with other lead clones for characterization and functional studies (**Fig. 6b**). BLI data showed that Clone 13A  
4 has a low double-digit Kd value (**Fig. 6c**).  
5

6 Clone 13A also potently neutralized WT/WA1 and B.1.617 pseudoviruses (single-digit ng/mL IC<sub>50</sub>) (**Fig. 6d**).  
7 We also performed authentic virus neutralization assays with Clone 13A, along with Clone 2, Clone 6 and two  
8 EUA antibodies (RGEN 10933 and 10987). Clones 2, 6 and 13A all potently neutralized SARS-CoV-2  
9 WA1/2020 and Delta variant authentic viruses (**Fig. 6e**). Against Delta variant, RGEN 10933 has a 1.6x drop  
10 in potency, Clone 13A has a 2x drop, Clone 2 has a 4x drop, Clone 6 has an 18x drop, while RGEN 10987 has  
11 a 52x drop.  
12

13 We also performed *in vivo* challenge experiment with Clone 13A using authentic viruses (**Fig. 6f-h**). Similar  
14 to the prior results all (8/8, 100%) mice in the placebo group developed severe disease due and succumbed  
15 from infection (**Fig. 6f,h**). In contrast, all mice receiving Clone 13A (9/9, 100%) maintained body weight  
16 throughout the duration of the study and survived from SARS-CoV-2 WA1 infection (**Fig. 6g,h**). We also  
17 tested Clone 13A against the Delta variant authentic virus challenge. All (8/8, 100%) mice in the placebo group  
18 developed severe disease due and succumbed from infection (**Fig. 6i**). In contrast, all mice receiving Clone  
19 13A (8/8, 100%) maintained body weight throughout the duration of the study (**Fig. 6j**). Of note, the Delta  
20 virus appeared to be not lethal for hACE2 mice within the experimental setting, thus the survival benefit can  
21 not be measured against Delta. These data confirmed that the humanized Clone 13A maintained its potency  
22 and protective activity *in vivo* against authentic SARS-CoV-2, both the original WA1 and Delta variant in the  
23 B.1.617 lineage.  
24

## 25 Discussion

26 The ongoing COVID-19 pandemic and continued emergence of SARS-CoV-2 variants has necessitated the  
27 rapid development of therapeutic interventions. The discovery and development of neutralizing antibodies with  
28 expanding collections of epitopes are critical to provide countermeasure options against escape seen with  
29 emerging variants of concern. We combined SARS-CoV-2 Spike RBD protein immunization with high-  
30 throughput single cell BCR sequencing technology to establish a platform to develop neutralizing antibody  
31 candidates. We identified two highly potent and specific SARS-CoV-2 neutralizing mAb clones with single-  
32 digit nanomolar affinity and low-picomolar avidity. We also generated a bispecific antibody of these two lead  
33 clones, as well as a potent humanized clone. The lead antibodies showed strong neutralization ability against

SARS-CoV-2 mAbs and CryoEM structures

1 SARS-CoV-2 and the highly transmissible B.1.617 lineage that poses a risk of reducing the efficacy of  
2 currently available therapeutic antibodies and prophylactic vaccines.  
3

4 The SARS-CoV-2 spike protein is dynamic, and three conformations of spike prefusion trimers have been  
5 detected on intact virions: all RBDs down, 1 RBD up, and 2 RBDs up, with the last one only existing in vitro  
6 with multiple stabilizing mutations<sup>55</sup>. The spike RBD needs to extend upwards to be accessible to ACE2, and  
7 the presence of host ACE2 changes the population distribution of different spike conformations by promoting  
8 the RBD towards the up/open state favorable for ACE2 binding<sup>56</sup>. Genetic variations in spike can also change  
9 the conformational equilibrium of the trimer, subsequently affecting virus infectivity<sup>57</sup>. Although antibody  
10 therapy has been developing rapidly to prevent or treat SARS-CoV-2 infection, the precise determinants of  
11 neutralization potency remain unclear. In addition to direct receptor blockade by antibody binding, modulation  
12 of spike-mediated membrane fusion by altering the ACE2-triggered spike protein conformational cycle has  
13 been suggested as another determinant of the antibody neutralization potency<sup>51</sup>.  
14

15 Depending on the binding mode, some antibodies may facilitate the spike conformational cycle to the final  
16 stage with all 3 RBDs open, or lock the spike trimer in a pre-fusion state, therefore enhancing or inhibiting the  
17 cell membrane fusion and syncytium formation. Based on our cryo-EM analysis, Clone 6 Fab binds to spike  
18 trimer preferentially with at least one RBD down, and effectively skews the spike trimer towards pre-fusion  
19 states (**Fig. 2b**). Besides making two neighboring down-RBDs inaccessible for ACE2 binding (**Extended Data**  
20 **Fig. 4c and 4d**, left panels), a down-RBD-binding Clone 6 Fab can also interact with an adjacent up-RBD  
21 through a quaternary epitope located at the side wall of the up-RBD (**Extended Data Fig. 4d**, right), which  
22 clashes with ACE2 binding (**Extended Data Fig. 4e**, right), thereby directly blocking ACE2 access to two  
23 RBDs simultaneously. This bipartite binding mode presumably is more stable than the single binding mode  
24 with the up-RBD alone, explaining why no spike trimer with all 3 RBDs open was detected when complexed  
25 with Clone 6 Fab. We hypothesize that the Clone 6 Fab binding to this secondary epitope of RBD helps lock  
26 the spike trimer in the pre-fusion form, which inhibits the spike-mediated cell membrane fusion by historical  
27 virus and even the B.1.1.7 variant that has enhanced binding affinity to ACE2<sup>58</sup> (**Extended Data Fig. 2d-e**,  
28 middle). In contrast, due to the different binding conformations of Clone 2 Fab on spike RBD, the spike trimer  
29 has been detected in skewed states that favorite RBDs up (**Fig. 2a**), which mimics the effect of ACE2 binding  
30 during the conformational cycle of the spike trimer. Nonetheless, we found that Clone 2 Fab also efficiently  
31 suppresses spike-mediated cell-cell fusion<sup>51</sup> (**Extended Data Fig. 2d-e**, left), suggesting that the mechanism  
32 determining the neutralization potency of spike-targeting antibody is complex.  
33

SARS-CoV-2 mAbs and CryoEM structures

1 Antibody resistance of SARS-CoV-2 B.1.1.7, B.1.351, and B.1.617 lineage variants has been reported <sup>7,14,59</sup>.  
2 The B.1.1.7 variant of SARS-CoV-2 spike contains a single mutation (N501Y) in the RBD, which has been  
3 reported to enhance the spike RBD-ACE2 binding affinity that could disfavor antibody neutralizations  
4 competing with ACE2 for RBD binding <sup>58</sup>. N501 does not directly interact with either Clone 2 or Clone 6 Fab,  
5 although the mutation may generate allosteric effects on other CDRL loops nearby to disrupt the binding  
6 interface <sup>58</sup>. While the B.1.1.7 variant spreads faster, has higher case-fatality rate, and some antibody resistance,  
7 it does not reduce the efficacy of the currently approved vaccines <sup>7,60-62</sup>. In contrast, the B.1.1351 variant of  
8 SARS-CoV-2 showed increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine  
9 efficacy <sup>6-8,61</sup>. In addition to the N501Y mutation, the B.1.351 variant has two additional point mutations  
10 K417N and E484K in spike RBD, which perturbs the RBD epitope recognition by both antibody clones,  
11 explaining their reduced potencies against the B.1.351 variant. The lineage B.1.617 has mutations in spike  
12 including G142D, E154K, L452R, E484Q, D614G, P681R, and Q1071H <sup>15</sup>, which could affect a number of  
13 leading therapeutic antibodies tested to date <sup>14,63,64</sup>. The L452R variant evades cellular immunity and increases  
14 infectivity <sup>65</sup>. L452R and S477N might affect the potency of Clones 2 and 6 to some degree based on the  
15 structure.

16

17 Several therapeutic antibodies have been granted EUA for clinical use by the FDA, such as two from  
18 Regeneron developed in a previous study <sup>66</sup>. Recent studies showed that some of the EUA mAbs have  
19 significant reduction in neutralization activities against B.1.617 lineage variants <sup>14,63</sup>. Many antibodies have  
20 been developed by the field and tested against various VoCs <sup>64,67,68</sup>. Our data also showed that RGEN 19087  
21 has substantially diminished potency against Delta. To better understand impact of Delta mutations on  
22 antibody neutralization potency, we performed structural analysis with the Delta RBD (**Extended Data Fig.**  
23 **8**). The epitopes of REGN-10987 centered around the RBD left shoulder loop on the  $\beta$ 1 end, which hereafter  
24 we termed left shoulder loop 1 (**Extended Data Fig. 8**). Clone 2 primarily targets a region at the right ridge of  
25 RBD. The L452R mutation of Delta is on the C-terminus edge of the left shoulder loop 1 and is critical for the  
26 loop 1 conformation. L452R is observed to favor an orientation interacting with the Y351 and is likely to  
27 disrupt the original conformation of left shoulder loop 1, consistent with the reduction of the affinity and potency  
28 of the REGN-10987 antibody. The E484Q, on the other hand, was not observed to significantly change side  
29 chain orientation and is less likely to cause drastic conformational changes on nearby loops. The mutation  
30 induced side-chain orientation as well as nearby loop conformation change plus distinct antibody targeting  
31 epitopes are consistent with the observation that Clone 2 retained its neutralization potency against Delta,  
32 whereas REGN-10987 did not.

33

## SARS-CoV-2 mAbs and CryoEM structures

1 In summary, in a concerted global effort against COVID-19, a number of candidate therapeutics, antibodies,  
2 and vaccines have been developed to date<sup>69</sup>. Our lead antibody clones are distinct different from existing  
3 antibodies reported to date in their binding geometry and footprints, are highly inhibitory against SARS-CoV-  
4 2 and several variants of concerns, particularly the Delta variant from the B.1.617 lineage. These antibodies  
5 thus expand the repertoire of COVID-19 countermeasures against the SARS-CoV-2 pathogen and its emerging  
6 and potentially more dangerous variants.

7

8

### 9 Acknowledgments

10 We thank various members from Chen, Xiong and Wilen labs for discussions and support. We thank Dr.  
11 Bieniasz for providing pseudovirus reporter plasmids. We thank staffs from various Yale core facilities (Keck,  
12 YCGA, HPC, Biophysics, YARC, Cryo-EM, CBDS and others) for technical support. We thank various  
13 support from Departments of Genetics, MBB, Laboratory Medicine, Immunobiology, Internal Medicine and  
14 Pharmacology; Institutes of Systems Biology and Cancer Biology; Dean's office of Yale School of Medicine  
15 and the office of Vice Provost for Research.

16

17 This work is supported by DoD PRMRP IIAR (W81XWH-21-1-0019) and discretionary funds to SC;  
18 discretionary funds to YX; Ludwig Foundation, Mathers Foundation, Burroughs Wellcome Fund, NIH K08  
19 AI128043, NIH R01 AI148467 to CBW; NIH R01 AI157155 to MSD; NIH/NIAID R01 AI150334 to RS.  
20 YCGA / HPC were supported by NIH Award 1S10OD018521. The T200 Biacore instrumentation was  
21 supported by NIH Award S10RR026992-0110.

22

### 23 Declaration of Interest

24 A patent application has been filed by Yale University on the antibodies described here. Yale University has  
25 committed to rapidly executable nonexclusive royalty-free licenses to intellectual property rights for the  
26 purpose of making and distributing products to prevent, diagnose, and treat COVID-19 infection during the  
27 pandemic and for a short period thereafter. M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda  
28 Biosciences, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome.  
29 The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir  
30 Biotechnology, Moderna, and Emergent BioSolutions.

31

32

### 33 Methods

1 **Institutional Approval**

2 This study has received institutional regulatory approval. All recombinant DNA (rDNA) and biosafety work  
3 were performed under the guidelines of Yale Environment, Health and Safety (EHS) Committee with approved  
4 protocols (Chen-15-45, 18-45, 20-18, 20-26; Xiong-17302; Wilen-18/16-2). All animal work was performed  
5 under the guidelines of Yale University Institutional Animal Care and Use Committee (IACUC) with approved  
6 protocols (Chen-2018-20068; Chen-2020-20358; Wilen-2018-20198).

7

8 **Animal immunization**

9 Standard 28-day repetitive immunization protocol was utilized to for immunization. *M. musculus* (mice), 6-12  
10 weeks old females, of C57BL/6J and BALB/c strains, were used for immunization. First, all mice are ear-  
11 marked and around 200  $\mu$ l blood was taken as pre-immunization sample, where serum was collected from the  
12 blood by centrifugation (1,000 g for 10 min). Two days later (day 0), for each mouse, 20  $\mu$ g SARS-CoV-2  
13 RBD-his tag protein (Sino biological) in 100  $\mu$ l PBS was mixed with 100  $\mu$ l Complete Freund's Adjuvant  
14 (CFA) with 3-way stop Cock. The fully emulsified mixture was subcutaneously injected into the back of each  
15 mouse. On day 7, a second immunization was performed, where each mouse was injected subcutaneously with  
16 20  $\mu$ g RBD-his tag protein fully emulsified with Incomplete Freund's Adjuvant (IFA). On day 13, around 50  
17  $\mu$ l of blood from each mouse was obtained for serum preparation as first bleeds. On day 14, a third  
18 immunization is performed, where all the procedures were similar to the second immunization. On day 20,  
19 second bleeds were taken. On day 21, forth immunization is performed, where all the procedures were similar  
20 to the second immunization. On day 24, each mouse receives 20  $\mu$ g RBD-his tag protein in 200  $\mu$ l PBS  
21 intraperitoneally as final immunization. On day 28, mice with strong serum conversion detected by ELISA  
22 were sacrificed. Spleen, lymph nodes, and bone marrow were collected for B cells isolation and purification  
23 for single cell BCR sequencing. Serums from pre, first and second bleeds were subjected to ELISA for anti-  
24 RBD tilter determination.

25

26 **Mouse B cell isolation and purification**

27 Primary B cells from spleen, draining lymph nodes, bone marrow of RBD-his tag protein immunized mice  
28 were isolated and purified with mouse CD138 MicroBeads (Miltenyi Biotec, 130-098-257) following standard  
29 protocol provided by the manufacturer. Spleens and draining lymph nodes were homogenized gently. Bone  
30 marrows were fragmented, rinsed with PBS containing 2% FBS, and filtered with a 100  $\mu$ m cell strainer (BD  
31 Falcon, Heidelberg, Germany). The cell suspension was centrifuged for 5 min with 400 g at 4 °C. Erythrocytes  
32 were lysed briefly using ACK lysis buffer (Lonza) with 1mL per spleen for 1~2 mins before adding 10 mL  
33 PBS containing 2% FBS to restore iso-osmolarity. The single-cell suspensions were filtered through a 40  $\mu$ m

## SARS-CoV-2 mAbs and CryoEM structures

1 cell strainer (BD Falcon, Heidelberg, Germany). CD138 positive B cells were isolated using magnetic cell  
2 sorting by positive selection according to the manufacturer's instructions. Cell samples post-magnetic selection  
3 were counted and prepared for single cell BCR sequencing.  
4

### 5 **Single cell BCR sequencing**

6 The enriched CD138<sup>+</sup> plasma cells and progenitor B cells were loaded on a 10X Chromium Next GEM Chip  
7 G. The target cell number was 10,000 cells per sample. Single-cell lysis and RNA first-strand synthesis were  
8 performed using Chromium Next GEM Single Cell 5' Gel Bead V3.1 according to the manufacturer's protocol.  
9 The following RNA and V(D)J library preparation was performed according to the manufacturer's protocol  
10 (Chromium Next GEM Single Cell V(D)J reagent kit, mouse BCR). The resulting VDJ-enriched libraries were  
11 sequenced following the reading mode recommended by 10x Genomics. Sequencing was performed on a  
12 NovaSeq targeted for 10,000 reads/cell, with a total of 100 million reads.  
13

### 14 **Single cell VDJ sequencing data analysis**

15 Raw sequencing data were processed using Cell Ranger v3.1.0 with default settings, aligning the reads to the  
16 GRCm38 mouse VDJ reference. Outputs from Cell Ranger were then visualized using the Loupe V(D)J  
17 Browser for quality control assessment and to identify the top enriched clonotypes. The consensus amino acid  
18 sequences for the top-ranked heavy/light chain pairs in each sample were then extracted and codon-optimized  
19 for human expression.  
20

### 21 **Plasmid construction**

22 The cDNA sequences of the paired variable heavy and light chain region of anti-RBD antibody clones were  
23 synthesized as gBlocks (IDT) and cloned by the Gibson assembly (NEB) into human IgG1 heavy chain and  
24 light chain expression plasmids, pFUSEss-CHIg-hG1(InvivoGen, pfusess-hchg1) and pFUSE2ss-CLIg-hK  
25 (InvivoGen, pfuse2ss-hclk), respectively. pFUSEss-CHIg-hG1 plasmid is a cloning plasmid that expresses the  
26 constant region of the human IgG1 heavy chain and includes multiple cloning sites to enable cloning of the  
27 heavy chain (CH) variable region. Parallelly, pFUSE2-CLIg-hK is a cloning plasmid that expresses the  
28 constant region of the human kappa light chain and contains multiple cloning sites to enable cloning of the  
29 light chain variable region. For anti-RBD antibody clones' heavy chain plasmid cloning, gBlocks, containing  
30 cDNA sequence of variable region of heavy chain of anti-RBD antibody clones and the regions overlapping  
31 with corresponding flanking sequences of EcoRI and NheI restriction sites pFUSEss-CHIg-hG1, were ordered  
32 from IDT. pFUSEss-CHIg-hG1 were digested with EcoRI and NheI restriction enzyme (ThermoFisher). These  
33 synthesized gBlocks were cloned into gel-purified restriction enzyme digested backbone by the Gibson

## SARS-CoV-2 mAbs and CryoEM structures

1 assembly (NEB). For anti-RBD antibody clones' light chain plasmid cloning, gBlocks, containing cDNA  
2 sequence of variable region of light chain of anti-RBD antibody clones and the regions overlapping with  
3 corresponding flanking sequences of EcoRI and BsiWI restriction sites pFUSE2ss-CL Ig-hK, were ordered  
4 from IDT. The gBlocks were then cloned into the pFUSE2ss-CL Ig-hK backbone, which was digested with  
5 EcoRI and BsiWI restriction enzyme (ThermoFisher).

6

7 The bi-specific antibody with the same Fab regions of clone 2 and clone 6 was generated by using the  
8 CrossMab-KiH bi-specific constructs <sup>70</sup>. The CrossMab-KiH bi-specific constructs were designed and  
9 generated basing on pFUSEss-CH Ig-hG1 and pFUSE2ss-CL Ig-hK. The bi-specific antibody consists of two  
10 hetero-half IgG1, one is knob IgG1 and the other is hole IgG1 (Knob-in-Hole conformation). Four plasmids  
11 were employed: pFUSE2ss-knobLight-hK, pFUSE2ss-knobheavy-hG1, pFUSE2ss-HoleLight-hK,  
12 pFUSE2ss-HoleHeavy-hG1. The pFUSE2ss-knobLight-hK is pFUSE2ss-CL Ig-hK with no further editing.  
13 The pFUSE2ss-knobheavy-hG1 contains two knob mutations (T366W, S354C) in the CH3 region when  
14 compared with pFUSEss-CH Ig-hG1. The gBlock (pPR024), containing constant region of heavy chain with  
15 two knob mutations and the regions overlapping with corresponding flanking sequences of NsiI and NheI  
16 restriction sites in pFUSEss-CH Ig-hG1 was ordered from IDT, and then cloned into NsiI and NheI restriction  
17 enzymes digested pFUSEss-CH Ig-hG1 backbone by the Gibson assembly (NEB). The pFUSE2ss-HoleLight-  
18 hK was generated by replacing the constant region of Light chain (CL) in pFUSE2ss-CL Ig-hK with CH1  
19 region of heavy chain in pFUSEss-CH Ig-hG1 vector. The CH1 region were PCR amplified from pFUSEss-  
20 CH Ig-hG1 vectors with a forward primer (oPR81-F) and a reverse primer (oPR82-R) containing regions  
21 overlapping with corresponding flanking sequences of the and NcoI and NheI restriction sites in the  
22 pFUSE2ss-CL Ig-hK. CH1 PCR amplified fragments were gel-purified and cloned into restriction enzyme  
23 digested pFUSE2ss-CL Ig-hK by the Gibson assembly (NEB). The pFUSE2ss-HoleHeavy-hG1 possesses three  
24 "hole" mutations (T366S, L368A, Y407V) in the CH3 region and a Y349C on the "hole" side to form a  
25 stabilizing disulfide bridge. In addition, to get the correct association of the light chain and the cognate heavy  
26 chain, the CH1 region in the pFUSE2ss-HoleHeavy-hG1 was exchanged with constant region of light chain  
27 (CrossMab conformation). The gBlock (pPR023), containing cDNA sequence of constant region of light chain,  
28 CH2 and CH3 with "hole" mutations, and regions overlapping with corresponding flanking sequences of NsiI  
29 and NheI restriction sites in pFUSEss-CH Ig-hG1 was ordered from IDT, and cloned into NsiI and NheI  
30 restriction enzymes digested pFUSEss-CH Ig-hG1 backbone through Gibson assembly (NEB). All plasmids  
31 were sequenced and Maxiprepped for subsequent experiments.

32

### 33 Cloning of SARS-CoV-2 spike variants

## SARS-CoV-2 mAbs and CryoEM structures

1 The construct of wild-type (WT) SARS-CoV-2 ectodomain of spike trimer is a gift from Dr. Jason S. McLellan  
2 at University of Texas at Austin<sup>34</sup>. The recently emerged SARS-CoV-2 spike SA variant B.1.351<sup>7</sup> and Indian  
3 variant B.1.617<sup>11</sup> was generated by standard cloning. The pVP21-SA variant includes four mutations in the  
4 N-terminal domain (L18F, D80A and D215G, R246I), three mutations at key residues in the RBD (N501Y,  
5 E484K and K417N), and one is in loop 2 (A701V). The pVP28-Indian variant includes seven mutations in  
6 Spike G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H. The pVP21-SA and pVP28-Indian were  
7 generated based on pcDNA3.1-pSARS-CoV-2-S, which was derived by insertion of a synthetic human codon-  
8 optimized cDNA (Geneart) encoding a WA1 SARS-CoV-2 S protein. For pVP21-SA-variant, two gBlocks,  
9 contains mutations in SA variant regions overlapping with corresponding flanking sequences of NheI and  
10 BsrGI restriction sites pcDNA3.1-pSARA-CoV-2. The gBlocks were then cloned into pcDNA3.1-pSARA-  
11 CoV-2 backbone, digested with NheI and BsrGI restriction enzyme (Thermo fisher) through Gibson assembly.  
12 For pVP28-Indian, four gBlocks, contains mutations in Indian variant regions overlapping with corresponding  
13 flanking sequences of NheI and BamHI restriction sites pcDNA3.1-pSARA-CoV-2. The gBlocks were then  
14 cloned into pcDNA3.1-pSARA-CoV-2 backbone, digested with NheI and BamHI restriction enzyme (Thermo  
15 fisher) through Gibson assembly. For the HIV1-based SARS-CoV-2 spike pseudotyped virus generation, WT  
16 pcDNA3.1-pSARS-CoV-2-S, pVP21-SA-variant, and pVP28-Indian variant lacking the C-terminal 19 codons  
17 were employed. A pair of forward and reverse primers were utilized to amplify fragments lacking the C-  
18 terminal 19 codons with pVP21-SAvariant and pVP28-Indian variant as template separately. The amplified  
19 fragments were gel-purified and cloned into pVP21-SAvariant backbone and pVP28-Indianvariant backbone,  
20 digested with BbvCI and BamHI.

21

## 22 Cell culture

23 HEK293FT (ThermoFisher) and 293T-hACE2 (gifted from Dr. Bieniasz' lab) cell lines were cultured in  
24 complete growth medium, Dulbecco's modified Eagle's medium (DMEM; Thermo fisher) supplemented with  
25 10% Fetal bovine serum (FBS, Hyclone), 1% penicillin-streptomycin (Gibco) (D10 media for short). Cells  
26 were typically passaged every 1-2 days at a split ratio of 1:2 or 1:4 when the confluence reached at 80%.  
27 Expi293F<sup>TM</sup> (ThermoFisher) cells were cultured in Expi293<sup>TM</sup> Expression Medium (ThermoFisher) in 125-  
28 mL shaker flask in a 37 °C incubator with 8% CO<sub>2</sub> on an orbital shaker rotating at 125 rpm. For routine  
29 maintenance, Expi293F<sup>TM</sup> cells were grown to 3-5×10<sup>6</sup> cells/mL, then split to 0.3-0.5×10<sup>6</sup> cells/mL every 3  
30 days.

31

## 32 Expression and purification of WT SARS-CoV-2 ectodomain of spike trimer

## SARS-CoV-2 mAbs and CryoEM structures

1 The WT ectodomain of SARS-CoV-2 spike trimer was expressed in Expi293F cells. For 100 mL expression  
2 scale, 100  $\mu$ g construct DNA was mixed with 400  $\mu$ g polyethylenimine in 10 mL Opti-MEM® I Reduced-  
3 Serum Medium (ThermoFisher) for 30 mins, and then added into 90 mL Expi293F cells at a density of 2.5-  
4  $3 \times 10^6$  cells/mL for incubation, shaking at 125 rpm in a 37 °C incubator with 8% CO<sub>2</sub>. After 5 days, the medium  
5 with the secreted protein was harvested and loaded onto an ion exchange column. Fractions containing the  
6 target protein was pooled and further purified using a Ni-NTA affinity column, followed by size exclusion  
7 chromatography using a Superose 6 10/300 column (GE Healthcare) with a buffer of 30 mM Tris, pH 8.0, 100  
8 mM NaCl. The monodispersed peak containing the ectodomain of the spike trimer was pooled and  
9 concentrated for subsequent analysis.

10

### 11 Recombinant antibody generation

12 The top-ranked enriched IgG clones were selected and cDNAs of relative variable region of paired heavy- and  
13 light-chain were codon-optimized and cloned separately into human IgG1 heavy chain and light chain  
14 expression vectors, containing the human IgG1 constant regions (pFuse plasmids). IgG1 antibodies were  
15 expressed in Expi293F™ cells. ExpiFectamine 293 transfection kit (Thermo fisher) was utilized for heavy and  
16 light chain plasmids transfection following the manufacturer's instruction. After 5 days, the antibody  
17 containing supernatants were collected. Suitable amount of rProtein A Sepharose® Fast Flow beads (Cytiva)  
18 was pre-washed and added into supernatants. After overnight incubation at 4 °C, antibody bound protein A  
19 beads were collected with Poly-Prep® Chromatography Columns (BIO-RAD). After 3 times wash with DPBS,  
20 mAbs were eluted with Fab elution buffer, then neutralized with Tris-HCl. Buffer exchange was performed  
21 with Amicon Ultra-4 Centrifugal Filter (MilliporeSigma) to keep mAbs in PBS for following assays. The  
22 numbering of mAbs was based on the order of mouse immunization and cloning. Clones 1-4 were mAbs  
23 chosen from enriched clones from RBD-his tag protein immunized C57BL/6J mice. Clone 5-11 were mAbs  
24 chosen from RBD-his tag protein immunized BALB/c mice.

25

### 26 Bi-specific antibody generation

27 Clone 16 (Clone6-KiH-Clone2) bispecific antibody is a human IgG1-like bispecific antibody, generated based  
28 on CrossMab-KiH bispecific constructs, including pFUSE2ss-knobLight-hK, pFUSE2ss-knobheavy-hG1,  
29 pFUSE2ss-HoleLight-hK, pFUSE2ss-HoleHeavy-hG1. The design and generation of CrossMab-KiH bi-  
30 specific constructs was described in the above plasmid constructs parts. The variable region of Clone 6 heavy  
31 chain was cloned into pFUSE2ss-knobheavy-hG1 vector. The variable region of Clone 6 light chain was cloned  
32 into pFUSE2ss-knobLight-hK vector. Clone6-KiH-Clone2 bispecific antibody was expressed *in vitro* in  
33 Expi293F™ cells by co-transfecting four plasmids (clone 6 knob heavy chain plasmid, clone 6 knob light chain

SARS-CoV-2 mAbs and CryoEM structures

1 plasmid, clone 2 hole heavy chain plasmid, and clone 2 hole light chain plasmid) with ExpiFectamine 293  
2 transfection kit (Thermofisher). The expression and antibody purification protocol was similar to recombinant  
3 antibody expression described as above. The bi-specific antibody was efficiently purified by using rProtein A  
4 Sepharose Fast Flow antibody purification resin (Cytiva, Cat:#17127901).

5

## 6 **Antibody humanization**

7 In order to humanize the antibody, we first determine the six CDR loops from murine variable domains by  
8 using the online free program "IGBLAST" (<https://www.ncbi.nlm.nih.gov/blast/>). Followed by apply CDR-  
9 grafting technique and graft six CDR loops onto human acceptor frameworks. The framework template  
10 selection was based on sequence similarity to close human germline sequence, as well as homology to  
11 clinically validated germline sequences. Thereafter, we identify Vernier zone residues through CryoEM  
12 structure between Clone 2 and trimeric S protein of SARS-CoV-2 from parent antibody (FR residues of Clone  
13 2 within 5Å of trimeric S protein) and substitute the key residues into the human acceptor framework of Clone  
14 13A.

15

## 16 **ELISA**

### 17 *ELISA for Anti-serum Titer Determination.*

18 The antibody titers in sera from pre, first and second bleeds were determined using direct coating ELISA. The  
19 384-well ELISA plates (Corning) were coated with 3 µg/mL SARS-CoV-2 RBD-his tag protein (Sino) in PBS  
20 at 4°C overnight. After standard washing with PBS-T washing buffer (phosphate-buffered saline containing  
21 0.05% Tween 20), ELSIA plates were blocked with blocking buffer (2% bovine serum albumin dissolved in  
22 PBST and filtered) for 1 hr at room temperature. Serial dilutions of pre-immune, first and second immune anti-  
23 sera in blocking buffer were added into plates and for 1hr at room temperature. Plates were washed and  
24 incubated with relative goat anti-mouse IgG(H+L)/HRP (Thermo Fisher,1:5000) for 1 h at room temperature.  
25 Plates were washed and developed using TMB reagents as substrates (Biolegend) following the manufacturer's  
26 recommended protocol. Reaction was stop with stop solution (1M H<sub>3</sub>PO<sub>4</sub>) and absorbance at 450nm was  
27 recorded by a microplate reader (Perkin Elmer).

### 28 *ELISA for Anti-RBD antibody clones binding.*

29 SARS-CoV-2 RBD protein with 6 X Histidine (Sino) was coated at 3 µg/ml in PBS on a 384-well microtiter  
30 plate overnight at 4 °C. After standard washing with PBST and blocked with 2% (w/v) solution of BSA in  
31 PBST to remove nonspecific binding, purified anti-RBD antibodies were diluted proportionally in PBST+2%  
32 BSA and transferred to the washed and blocked microtiter plates. After one hour of incubation at RT, plates  
33 were washed, and RBD-his tag protein-bound antibody was detected with goat-anti-human IgG1 (H+L) with

SARS-CoV-2 mAbs and CryoEM structures

1 horseradish peroxidase (HRP) conjugated (Invitrogen,1:1000) The plates were washed and developed using  
2 TMB substrate solution (Biolegend) according to manufacturer's recommendation and absorbance at 450nm  
3 was measured on a microplate reader after the reaction was stopped by stop solution (1M H<sub>3</sub>PO<sub>4</sub>).  
4

## 5 **Affinity determination via bio-layer interferometry (BLI)**

6 Antibody binding kinetics for anti-spike mAbs were evaluated by BLI on an Octet RED96e instrument  
7 (FortéBio) at room temperature. Two types of measurements were performed. (1) HIS1K biosensors (FortéBio)  
8 were first loaded with his-tagged SARS-CoV-2 RBD protein to a response of about 1 nm, followed by a 60 s  
9 baseline step in the kinetic buffer (PBS, 0.02% Tween, pH7.4). After that, the biosensors were associated with  
10 indicated concentrations of the antibodies (from 50 nM to 0.78125 nM with 2-fold dilutions, where the kinetic  
11 buffer was served as the negative control) for 200 s, then dissociated in the kinetic buffer for 1000 s. (2) 25ng/ul  
12 of Clone13A-IgG1 antibodies were captured on a AHC biosensor (ForteBio). The baseline was recorded for  
13 60 s in a running buffer (PBS, 0.02% Tween-20, and 0.05% BSA, pH 7.4). Afterward, the sensors were  
14 subjected to an association phase for 500 s in wells containing RBD-his diluted in the buffer. In the dissociation  
15 step, the sensors were immersed in the running buffer for 1000 s. The dissociation constants KD, kinetic  
16 constants K<sub>on</sub> and K<sub>off</sub>, were calculated by using a 1:1 Langmuir binding model with FortéBio data analysis  
17 software.  
18

## 19 **Affinity measurement by surface plasmon resonance (SPR)**

20 Kinetics binding measurement for anti-spike mAbs in this study was performed using a Biacore T200  
21 instrument (GE Healthcare). The system was flushed with filtered 1xHBS-P+ running buffer (0.01M HEPES,  
22 0.15M NaCl and 0.05%v/v Surfactant P20, pH 7.4) and all steps were performed at 25°C chip temperature.  
23

### *24 Kinetics binding measurement on CM5 Chip (Series S Sensor Chip CM5)*

25 For kinetic binding measurements, CM5 chip surface was activated by injecting a solution of EDC/NHS (GE  
26 Healthcare). Mouse anti-human IgG (Fc) mAb (25 µg/ml) was immobilized on the sensor chip by amine  
27 coupling, followed by deactivation using 1M ethanolamine. Afterward, anti-spike mAbs (0.1 µg/ml) were then  
28 flowed over and captured on anti-human IgG (Fc) mAb-coated surface. Subsequently, gradient diluted his-  
29 tagged SARS-CoV-2 RBD solutions (1.875 nM-30 nM, two-fold serial dilution) were injected individually in  
30 single-cycle kinetic format without regeneration (30 µl/min, association:180s, dissociation:60s). The binding  
31 data were double referenced by blank cycle and reference flow cell subtraction. Processed data were fitted by  
32 1:1 interaction model using Biacore T200 Evaluation Software 3.1.

### *32 Kinetics binding measurement on NTA Chip*

## SARS-CoV-2 mAbs and CryoEM structures

1 For kinetic binding measurements, NTA chip was activated manually by loading a solution of NiCl<sub>2</sub>.  
2 Histidine-labelled SARS-CoV-2 RBD protein (0.075 µg/ml) was then flowed over the chip and captured on  
3 nickel-coated surface. Subsequently, gradient diluted anti-spike mAbs solutions (0.9875 nM-15 nM, two-fold  
4 serial dilution) were injected individually in single-cycle kinetic format without regeneration (30µl/min,  
5 association:240 s, dissociation:90 s). The binding data were double referenced by blank cycle and reference  
6 flow cell subtraction. Processed data were fitted by 1:1 interaction model using Biacore T200 Evaluation  
7 Software 3.1.

8

## 9 SARS-CoV-2 pseudovirus reporter and neutralization assays

10 HIV-1 based SARS-CoV-2 S pseudotyped virions were generated according to a previous study <sup>71</sup>. Two  
11 plasmids are adopted to generate HIV-1 based SARS-CoV-2 S pseudotyped virions. HIV-1 dual reporter  
12 vector expressing mCherry and luciferase (NL4-3 mCherry Luciferase, plasmid#44965) was purchased from  
13 Addgene. Plasmid expression a C-terminally truncated SARS-CoV-2 S protein (pSARS-CoV-2Δ19) was  
14 obtained from Dr Bieniasz' lab. In order to generate HIV-1 based SARS-CoV-2 S pseudotyped virions, 15x10<sup>6</sup>  
15 293FT cells were seeded in a 150 mm plates one day before in 20 ml D10 media. The following day, after the  
16 cell density reaches 90%, medium was discarded and replaced with 13 mL serum-free Opti-MEM medium. 20  
17 µg NL4-3 mCherry Luciferase reporter plasmids and 15 µg SARS-CoV-2 (pSARS-CoV-2Δ19) plasmids were  
18 mixed thoroughly in 225 µl serum-free Opti-MEM medium. Then 100 µl Lipofectamine 2000 (Invitrogen)  
19 were diluted in 225 µl serum-free Opti-MEM medium. Then the diluted plasmid mixture and Lipofectamine  
20 2000 were mixed thoroughly and incubated for 10 mins at RT before adding into cells. After 6 hr, the culture  
21 medium was changed back to the completed growth medium, 20 mL for one 150 mm plate. At 48 h after  
22 transfection, the 20 mL supernatant was harvested and filtered through a 0.45-µm filter, aliquoted and frozen  
23 in -80°C.

24

25 Parallelly, the three plasmids-based HIV-1 pseudotyped virus system were utilized to generate (HIV-  
26 1/NanoLuc2AEGFP)-SARS-CoV-2 particles and (HIV-1/NanoLuc2AEGFP)-SARS-CoV-2-SA variant  
27 particles. The reporter vector, pCCNanoLuc2AEGFP, and HIV-1 structural/regulatory proteins  
28 (pHIVNLGagPol) expression plasmid were gifts from Dr Bieniasz's lab <sup>71</sup>. Briefly, 293T cells were seeded in  
29 150 mm plates, and transfected with 21 µg pHIVNLGagPol, 21 µg pCCNanoLuc2AEGFP, and 7.5 µg of a  
30 SARS-CoV-2 SΔ19 or SARS-CoV-2 SA SΔ19 plasmid utilizing 198 µl PEI. At 48 h after transfection, the 20-  
31 ml supernatant was harvested and filtered through a 0.45-µm filter, and concentrated before aliquoted and  
32 frozen in -80°C.

33

## SARS-CoV-2 mAbs and CryoEM structures

1 The pseudovirus neutralization assays were performed on 293T-hACE2 cell line <sup>71</sup>. One day before, 293T-  
2 hACE2 cells were plated in a 96 well plate, 0.02 x10<sup>6</sup> cells per well. The following day, serial dilution of  
3 monoclonal IgG from 40 µg/mL (4-fold serial dilution using complete growth medium, 55 µL aliquots) were  
4 mixed with the same volume of SARS-CoV-2 pseudovirus. The mixture was incubated for 1 hr at 37 °C  
5 incubator, supplied with 5% CO<sub>2</sub>. Then 100 µL of the mixtures were added into 96-well plates with 293T-  
6 hACE2 cells. Plates were incubated at 37°C supplied with 5% CO<sub>2</sub>. 48 hr later, 1 µL D-luciferin reagent  
7 (Perkin Elmer, 33.3 mg/ml) was added to each well and incubated for 5 mins. Luciferase activity was measured  
8 with using a microplate spectrophotometer (Perkin Elmer). The inhibition rate was calculated by comparing  
9 the OD value to relative negative and positive control wells. For the three plasmids-based HIV-1 pseudotyped  
10 virus system, 293T cells were collected and the GFP+ cells were analyzed with Attune NxT Acoustic Focusing  
11 Cytometer (Thermo Fisher). The 50% inhibitory concentration (IC50) was calculated with a four-parameter  
12 logistic regression using GraphPad Prism 8.0 (GraphPad Software Inc.).  
13

### 14 Cell Fusion assay

#### 15 Vectors and plasmids

16 Plasmid encoding human ACE2 (hACE2) was obtained from Addgene (hACE2; catalog #1786). The hACE2  
17 2.6 kbp ORF was also blunt-cloned into a third generation HIV vector 3' of CMV promoter and 5' of an IRES-  
18 puro<sup>r</sup> cassette to generate pHIV-CMV-hACE2-IRES-Puro. It was inserted into a *piggybac* transposon (Matt  
19 Wilson of Baylor College of Medicine, along with the transposase plasmid pCMV-*piggybac*) that had been  
20 modified to encode a CMV-IRES-*bsd*<sup>r</sup> cassette; resultant plasmid was named pT-PB-SARS-CoV-2-Spike-  
21 IRES-Blasti. This too was inserted into *piggybac* transposon to make pT-PB-SARS-CoV-2-UK Spike-IRES-  
22 Blasti.  
23

#### Cell lines

24 The HOS cells were stably transduced with a third generation HIV vector encoding *tat*, along with eGFP,  
25 mRFP, and bleomycin resistance gene; they were maintained in 200-400 µg/mL phleomycin (Invivogen) and  
26 were eGFP and mRFP-positive by flow cytometry. hACE2 was subsequently introduced by VSV G-mediated  
27 HIV-based transduction using pHIV-CMV-hACE2-IRES-Puro to produce HOS-3734, which cell lines  
28 maintained in selection using 10 µg/mL puromycin (Sigma-Aldrich). TZMbl cells (#JC53BL-13) were  
29 obtained from the NIH AIDS Reagent Program. TZMbl cells stably expressing wild type S/UK variant S were  
30 created by co-transfecting TZMbl cells with pT-PB-SARS-CoV-2- Spike-IRES-Blasti or pT-PB-SARS-CoV-  
31 2-UK Spike-IRES-Blasti, respectively, along with pCMV-*piggybac* and resistant cells selected with 10 µg/mL  
32 blasticidin (Invivogen). The control TZMbl cell line not expressing S was generated by co-transfecting pCMV-  
33 *piggybac* with pT-pB-IRES-Blasti and selecting for blasticidin-resistant TZMbl cells.

1 *Cell fusion inhibition by monoclonal antibodies*

2 Producer cells (TZMbl-wild type Spike/ Tzmb1-UK Spike) and target cells (HOS-3734) were generated as  
3 described above. Ten thousand S-expressing cells (TZMbl-wild type Spike/TZMbl-UK Spike) in 100  $\mu$ L of  
4 medium in the absence of blasticidin were seeded in 96 well plates. After 24 h, 70  $\mu$ L of four-fold serially  
5 diluted antibody was added into producer cells and incubated at 37°C for 1 hour. At that time 10<sup>4</sup> target cells  
6 (HOS-3734) in 50  $\mu$ L medium were then added to the producer cells, and after another 24 h cells were lysed  
7 in 0.1 mL and RLU measured. Data were analyzed with non-linear regression using GraphPad Prism to  
8 determine the neutralization curve and the IC<sub>50</sub> values calculated.

9

10 ***In vitro* neutralization against authentic SARS-CoV-2**

11 SARS-CoV-1 (USA-WA1/2020) was produced in Vero-E6 cells and tittered as described previously <sup>72</sup>. SARS-  
12 CoV-2 neutralization was assessed by measuring cytotoxicity. 5x10<sup>5</sup> Vero-E6 cells were plated per well of a  
13 96-well plate. The following day, serial dilutions of antibodies were incubated with 2.5x10<sup>3</sup> plaque forming  
14 units (PFU) SARS-CoV-2 for 1 hour at room temperature. SARS-CoV-2 neutralization was assessed by  
15 measuring cytotoxicity. 5x10<sup>5</sup> Vero-E6 cells were plated per well of a 96-well plate. The following day, serial  
16 dilutions of antibodies were incubated with 2.5x10<sup>3</sup> PFU SARS-CoV-2 for 1 hour at room temperature. The  
17 medium was then aspirated from the cells and replaced with 100  $\mu$ l of the antibody/virus mixture. After 72  
18 hours at 37°C, 10  $\mu$ l of CellTiter- Glo (Promega) was added per well to measure cellular ATP concentrations.  
19 Relative luminescence units were detected on Cytaion5 (Biotek) plate reader. All conditions were normalized  
20 to an uninfected control. Each condition was done in triplicate in each of three independent experiments.

21

22 **Focus reduction neutralization test.**

23 Serial dilutions of mAbs or sera were incubated with 10<sup>2</sup> focus-forming units (FFU) of different strains or  
24 variants of SARS-CoV-2 for 1 h at 37°C. Antibody-virus complexes were added to Vero-TMPRSS2 cell  
25 monolayers in 96-well plates and incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v)  
26 methylcellulose in MEM supplemented with 2% FBS. Plates were harvested 24 h later by removing overlays  
27 and fixed with 4% PFA in PBS for 20 min at room temperature. Plates were washed and sequentially incubated  
28 with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57, and  
29 SARS2-71 <sup>4 73</sup>. The anti-S antibodies and HRP-conjugated goat anti-mouse IgG (Sigma, 12-349) in PBS  
30 supplemented with 0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2-infected cell foci were  
31 visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot microanalyzer  
32 (Cellular Technologies).

33

34 ***In vivo* efficacy testing against authentic SARS-CoV-2**

## SARS-CoV-2 mAbs and CryoEM structures

1 The efficacy of mAbs against replication-competent SARS-CoV-2 virus was evaluated *in vivo*, using both a  
2 prophylactic setting where the animals were treated with mAb prior to viral infection, and a therapeutic setting  
3 where the animals were treated post infection. These experiments were performed in an animal BSL3 (ABSL3)  
4 facility. The replication-competent SARS-CoV-2 (USA-WA1/2020) virus was produced in Vero E6 cells, and  
5 the titer was determined by plaque assay using WT VeroE6.

6

7 The K18-hACE2 mice (B6.Cg-Tg(K18-ACE2)2Prlmn/J) were purchased from the Jackson Laboratory and  
8 bred in house using a trio breeding scheme. Mice were sedated with isoflurane, and infected via intranasal  
9 inoculation of 2,000 PFU (20x LD50) SARS-CoV-2 (USA-WA1/2020) virus administered in 50uL of DPBS.  
10 Six to eight-week-old K18-hACE2 littermate-controlled mice, mixed gender (male / female) mice were divided  
11 randomly into three groups, and administered with 20 mg/kg (of mice body weight) Clone 2, Clone 6 or  
12 placebo / control, via intraperitoneal (IP) injection. For prophylactic experiment, the mAb drug / placebo  
13 treatment was 24h prior to infection; for therapeutic experiment, the treatment was 18h post-infection. The  
14 control for the prophylactic experiment was DPBS, and the control for the therapeutic experiment was isotype  
15 control hIgG1, where both controls are similar (no effect on disease progression). Survival, body conditions  
16 and weights of mice were monitored daily for 10 consecutive days.

17

### ***In vivo* efficacy testing of humanized Clone13A to authentic SARS-CoV-2 virus**

18 10-12-week-old littermate-controlled female and male K18hAce2Tg+ mice were pretreated with 20 mg/kg of  
19 either control hIgG1 (purchased from BioXCell) or clone 13A mAb (produced by the Chen lab) administered  
20 IP in 300 uL of DPBS. 24 hours later, mice were anesthetized with isoflurane, and SARS-CoV-2 isolate USA-  
21 WA1/2020, or Delta variant (B.1.617.2), was inoculated intranasally at a dose of  $2 \times 10^3$  PFU/mouse  
22 (determined using wild type Vero E6) in 50  $\mu$ L of DPBS. Weights were obtained daily for 10 days following  
23 infection, and mice were euthanized when morbid.

25

### **Fab generation**

26 The Fab fragments of Clone 2 and Clone 6 were generated from full length IgGs of Clone 2 and Clone 6 using  
27 a commercial PierceTM Fab Preparation Kit (Thermo Fisher). All procedures were performed following the  
28 manufacturer's instructions. Briefly, 2 mg the whole IgGs of Clone 2 and Clone 6 were digested with  
29 immobilized papain at 37 °C for 4 hr with rotation. Then protein A beads were applied to bind the Fc fragments  
30 and undigested IgG. Then Fab fragments were recovered in the flow-through fraction, and further purified by  
31 size exclusion chromatography using a Superdex 200 10/300 column (GE Healthcare) in 30 mM Tris pH 8.0,  
32 100 mM NaCl. The monodispersed peak of Fab fragments was pooled and concentrated for subsequent analysis.

1

## 2 Cryo-EM sample preparation and data collection

3 The purified SARS-CoV-2 spike trimer at a final concentration of 0.3 mg/mL (after mixture) was mixed with  
4 Clone 2 or Clone 6 Fab at a molar ratio of 1:2 at 4 °C for 30mins. Then 3 µl of the protein mixture was applied  
5 to a Quantifoil-Cu-2/1-3C grid (Quantifoil) pretreated by glow-discharging at 15 mA for 1 min. The grid was  
6 blotted at 4 °C with 100% humidity and plunge-frozen in liquid ethane using FEI Vitrobot Mark IV (Thermo  
7 Fisher). The grids were stored in liquid nitrogen until data collection.

8

9 Images were acquired on a FEI Titan Krios electron microscope (Thermo Fisher) equipped with a Gatan K3  
10 Summit direct detector in super-resolution mode, at a calibrated magnification of 81,000× with the physical  
11 pixel size corresponding to 1.068 Å. Detailed data collection statistics for the Fab-spike trimer complexes are  
12 shown in a supplemental table. Automated data collection was performed using SerialEM<sup>74</sup>.

13

## 14 Cryo-EM data processing

15 A total of 2,655 and 1,766 movie series were collected for Clone 2 Fab-S trimer complex and Clone 6 Fab-S  
16 trimer complex, respectively. The same data processing procedures were carried out for each complex as  
17 described below. Motion correction of the micrographs was carried out using RELION<sup>75</sup> and contrast transfer  
18 function (CTF) estimation was calculated using CTFFIND4<sup>76</sup>. Particles were picked automatically by  
19 crYOLO<sup>77</sup>, followed by 2D and 3D classifications without imposing symmetry. The 3D classes with different  
20 S trimer conformations were then processed separately by consensus 3D refinement and CTF refinement.  
21 Image processing and 3D reconstruction using cryoSPARC<sup>78</sup> produced similar results. For each state of the  
22 Clone 6 Fab-S trimer complex, multibody refinements were then carried out in RELION by dividing the  
23 complex into individual rigid bodies (3 refinements each with a rigid body containing a unique Fab, RBD, and  
24 the N-terminal domain (NTD) of spike S1 subunit, and another rigid body for the rest of the spike ectodomain  
25 trimer). For each state of the Clone 2 Fab-S trimer complex, local masked 3D classification without image  
26 alignment was performed focusing on one Fab-RBD region and the best class of particles was selected for  
27 consensus refinement of the whole complex. Subsequently, multibody refinement was performed as described  
28 above for the rigid body containing the focused region. The 3D reconstruction of the other Fab-RBD regions  
29 were obtained with the same procedure. The final resolution of each reconstruction was determined based on  
30 the Fourier shell correlation (FSC) cutoff at 0.143 between the two half maps<sup>79</sup>. The final map of each body  
31 was corrected for K3 detector modulation and sharpened by a negative B-factor estimated by RELION<sup>80</sup>, and  
32 then merged in Chimera for deposition. The local resolution estimation of each cryo-EM map is calculated by  
33 RELION<sup>75</sup>. See also **Extended Data Fig. 7 and Table 1**.

1

## 2 **Model building and refinement**

3 The structure of the ectodomain of SARS-CoV-2 spike trimer (PDB 6VSB) was used as an initial model and  
4 docked into the spike trimer portion of the cryo-EM maps using Chimera <sup>81</sup>. The initial models of Clone 2 and  
5 Clone 6 Fabs were generated by homology modeling using SWISS-MODEL <sup>82</sup>, and then docked into the Fab  
6 portions of the cryo-EM maps using Chimera <sup>81</sup>. The initial models were subsequently manually rebuilt in  
7 COOT <sup>83</sup>, followed with iterative cycles of refinement in Refmac5 <sup>84</sup> and PHENIX <sup>85</sup>. The final models with  
8 good geometry and fit to the map were validated using the comprehensive cryo-EM validation tool  
9 implemented in PHENIX <sup>86</sup>. All structural figures were generated using PyMol (<http://www.pymol.org/>) and  
10 Chimera <sup>81</sup>.

11

## 12 **Homology modeling of SARS-CoV-2 variants**

13 The structural models of SARS-CoV-2 variants of RBD were generated by SWISS model<sup>82</sup> using the wildtype  
14 / WA RBD Cryo-EM structure as a template. The generated structures were aligned with the wild-type RBD  
15 in complex with Clone 2, Clone 6, and/or other mAbs. The cryo-EM structures and homology models were  
16 analyzed in Pymol.

17

## 18 **Replication, randomization, blinding and reagent validations**

19 Replicate experiments have been performed for all key data shown in this study.

20 Biological or technical replicate samples were randomized where appropriate. In animal experiments, mice  
21 were randomized by cage, sex and littermates.

22 Experiments were not blinded.

23 Commercial antibodies were validated by the vendors, and re-validated in house as appropriate. Custom  
24 antibodies were validated by specific antibody - antigen interaction assays, such as ELISA. Isotype controls  
25 were used for antibody validations.

26 Cell lines were authenticated by original vendors, and re-validated in lab as appropriate.

27 All cell lines tested negative for mycoplasma.

28

## 29 **Data, resources and code availability**

30 All data generated or analyzed during this study are included in this article and its supplementary information  
31 files. Specifically, source data and statistics for non-high-throughput experiments are provided in a  
32 supplementary table excel file. High-throughput experiment data are provided as processed quantifications in  
33 Supplemental Datasets. Genomic sequencing raw data are deposited to Gene Expression Omnibus (GEO) with

SARS-CoV-2 mAbs and CryoEM structures

1 the accession code (GSE174635). The models of the mAb:Spike complexes have been deposited in the  
2 wwPDB with accession codes (3dSpike-Fab6, 7MW2; 2dSpike-Fab6, 7MW3; 1dSpike-Fab6, 7MW4;  
3 2uSpike-Fab2, 7MW5; 3uSpike-Fab2, 7MW6). The cryo-EM maps of the mAb:Spike complexes have been  
4 deposited in EMDB with accession codes (3dSpike-Fab6, EMD-24060; 2dSpike-Fab6, EMD-24061; 1dSpike-  
5 Fab6, EMD-24062; 2uSpike-Fab2, EMD-24063; 3uSpike-Fab2, EMD-24064), respectively. Codes that  
6 support the findings of this research are being deposited to a public repository such as GitHub. Additional  
7 information related to this study are available from the corresponding authors upon reasonable request.  
8

1  
2  
3

**Table 1. Cryo-EM Data Collection and Refinement Statistics**

	3dSpike-Fab6 (PDB 7MW2) (EMD-24060)	2dSpike-Fab6 (PDB 7MW3) (EMD-24061)	1dSpike-Fab6 (PDB 7MW4) (EMD-24062)	2uSpike-Fab2 (PDB 7MW5) (EMD-24063)	3uSpike-Fab2 (PDB 7MW6) (EMD-24064)
<b>Data collection and processing</b>					
Magnification	81000	81000	81000	81000	81000
Voltage (kV)	300	300	300	300	300
Electron exposure (e-/Å <sup>2</sup> )	66.5	66.5	66.5	66.5	66.5
Defocus range (μm)	-0.8 to -1.8				
Pixel size (Å)	1.068	1.068	1.068	1.068	1.068
Symmetry imposed	C3	C1	C1	C1	C1
Initial particle images (no.)	655318			1013040	
Final particle images (no.)	68416	111449	80954	135336	181380
Map resolution (Å) FSC threshold	2.97	3.15	3.42	3.42	3.22
<hr/>					
<b>Refinement</b>					
Map sharpening <i>B</i> factor (Å <sup>2</sup> )	-81 to -91	-69 to -127	-76 to -142	-74 to -189	-80 to -100
Model map FSC (masked)	0.83	0.81	0.74	0.67	0.69
Model composition					
Non-hydrogen atoms	33807	33825	33741	33661	35247
Protein residues	4293	4293	4290	4245	4446
Ligands	72	72	74	83	87
<i>B</i> factors (Å <sup>2</sup> )					
Protein	41	46	63	118	39
Ligand	80	69	94	156	62
R.m.s. deviations					
Bond lengths (Å)	0.003	0.003	0.003	0.003	0.004
Bond angles (°)	0.6	0.6	0.6	0.7	0.8
Validation					
MolProbity score	1.6	1.7	1.8	2.2	2.0
Clashscore	7.1	7.5	8.7	14.1	11.0
Poor rotamers (%)	0.08	0.08	0.11	0.08	0.11
Ramachandran plot					
Favored (%)	96.68	96.09	95.64	91.39	94.27
Allowed (%)	3.15	3.55	4.15	8.03	5.06
Disallowed (%)	0.17	0.36	0.21	0.57	0.66

\*3dSpike-Fab6: Spike trimer with 3 RBDs down in complex with Fab clone 6; 2dSpike-Fab6: Spike trimer with 2 RBDs down in complex with Fab clone 6; 1dSpike-Fab6: Spike trimer with 1 RBD down in complex with Fab clone 6; 2uSpike-Fab2: Spike trimer with 2 RBDs up in complex with Fab clone 2; 3uSpike-Fab2: Spike trimer with 3 RBDs up in complex with Fab clone 2.

4  
5

1

## 2 Figure Legends

3

### 4 **Figure 1 | Immunization-single B cell sequencing leads to development of potent monoclonal antibodies 5 in both monospecific and bispecific forms**

6 a, Frequency distribution of immunoglobulin isotypes in SARS-CoV-2 Spike RBD immunized mice. (Top)  
7 Analysis of isotypes in both bone marrow and spleen in RBD immunized C57BL/6J mice. (Bottom) Analysis  
8 of isotypes in RBD immunized C57BL/6J and BALB/c mice.

9 b, CDR3 sequences of heavy and light chains of the top enriched antibody clones from RBD-his tag immunized  
10 C57BL/6J mice (Top) and BALB/c mice (Bottom).

11 c, Octet measurement of binding strengths top SARS-CoV-2 RBD-specific monospecific mAb clones (Clones  
12 2 and 6). The binding was particularly strong, thus that the dissociation stage was never observed in this BLI  
13 assay.

14 d, SPR measurement of binding strengths top SARS-CoV-2 RBD-specific monospecific mAb clones (Clones  
15 2 and 6), using an NTA chip where the antigen (RBD) was fixed on the chip.

16 e, SPR measurement of binding strengths top SARS-CoV-2 RBD-specific monospecific mAb clones (Clones  
17 2 and 6), a humanized mAb clone (Clone 13), and a bispecific mAb (Clone 16), using a Fc chip where  
18 antibodies were fixed on the chip.

19 Source data and additional statistics for experiments are provided in a supplemental excel file.

20

### 21 **Figure 2 | Cryo-EM structures of the ectodomain of SARS-CoV-2 spike trimer in complex with Clone 2 22 or Clone 6 Fab and Structural comparisons**

23 a-b, Cryo-EM structures of the ectodomain of SARS-CoV-2 spike trimer in complex with Clone 2 (a) or Clone  
24 6 (b). Each Fab molecule is shown as ribbons in different colors, spike RBD is shown as dark gray ribbons,  
25 with the rest of spike trimer shown as gray surface. The particle distribution of each S trimer conformation is  
26 shown correspondingly.

27

### 28 **Figure 3 | Binding interfaces and epitopes of lead monoclonal antibodies**

29 a, Overlay of the structures of spike RBD from its complex with the host ACE2 receptor, Clone 2 or Clone 6  
30 Fab indicates both antibody clones directly block the ACE2 access.

31 b, Overlay of the structures of spike RBD from its complex with Clone 2 or Clone 6 Fab reveals a 17° rotation  
32 pivoted at the right ridge of spike RBD, resulting in less contact of Clone 2 Fab light chain with the left shoulder

SARS-CoV-2 mAbs and CryoEM structures

1 of spike RBD. The comparison of the Clone 2 and Clone 6 Fab binding interfaces with spike RBD is shown  
2 in the bottom parallel insets. The nomenclature of the top surface of spike RBD is described in the top inset.

3 **c**, The orientations of the three CDRH (upper panel) and CDRL (lower panel) loops of Clone 2 or Clone 6  
4 Fabs on spike RBD. The structures were overlaid with the RBD portions.

5 **d**, Left, overlay of Clone 2 and Clone 6 Fab molecules alone. The CDRH3 loops that have the largest  
6 conformational difference are highlighted in brighter colors (blue for clone 2 and red for clone 6). Lower inset,  
7 amino acid sequence alignment of the CDRH3 loops of both clones. Right, spike RBD residue F486, which is  
8 shown as orange sticks, has a large conformational change upon RBD binding to the two clones.

9 **e**, Comparison of spike RBD epitope regions for Clone 2 and Clone 6 Fabs, highlighted in cyan and magenta,  
10 respectively. The spike binding interface for hACE2 receptor is highlighted in yellow.

11

12 **Figure 4 | Lead mAb clones showed strong neutralization potency against WT/WA1 and B.1.617, with  
13 epitope and mutation analysis of the Fab-spike RBD interfaces**

14 **a**, Neutralization assay on top mAb clones using WT/WA1 SARS-CoV-2 Spike pseudotyped HIV1-lentivirus  
15 carrying an EGFP reporter (pseudovirus).

16 **b**, Neutralization assay on top mAb clones using B.1.351 variant SARS-CoV-2 Spike pseudovirus.

17 **c**, Neutralization assay on top mAb clones using B.1.617 variant SARS-CoV-2 Spike pseudovirus.

18 **d**, Neutralization assay on top mAb clones and their combination using WT/WA1 SARS-CoV-2 Spike  
19 pseudovirus.

20 **e**, Neutralization assay on top mAb clones and their combination using B.1.351 variant SARS-CoV-2 Spike  
21 pseudovirus.

22 **f**, Neutralization assay on top mAb clones and their combination using B.1.617 variant SARS-CoV-2 Spike  
23 pseudovirus.

24 **g**, Structural analysis of the spike RBD mutations from the B.1.351 (left panels) and B.1.617 (right panels)  
25 variants at the interfaces with Clone 2 and Clone 6 Fabs. The residues mutated in spike RBD are shown as  
26 gray sticks in wild-type (WT) spike and yellow in the B.1.351 variant and green in the B.1.617 variant. Another  
27 frequent RBD mutation S477N in SARS-CoV-2 strains is also shown as slate sticks. The spike RBD is shown  
28 as light gray ribbon, and the CDR loops of Clone 2 and Clone 6 Fabs are shown as cyan and magenta ribbons,  
29 respectively, with the WT RBD-interacting residues highlighted in brighter blue and red colors.

30

31 **Figure 5 | Lead monoclonal antibodies have potent prophylactic and therapeutic *in vivo* efficacy against  
32 replication competent SARS-CoV-2 virus.**

33 **a**, In vitro neutralization of top mAb clones against authentic SARS-CoV-2 in BL3 setting

SARS-CoV-2 mAbs and CryoEM structures

1 **b**, Schematics of *in vivo* efficacy testing of top mAb clones against lethal challenges of authentic SARS-CoV-  
2 in hACE2 transgenic mice at BL3 level, in both prophylactic (upper panel) and therapeutic (bottom panel)  
3 settings.

4 **c-e**, Prophylactic efficacy testing. **c and d**, Body weight curves of antibody and placebo (DPBS) treated hACE2  
5 transgenic mice under lethal challenges of authentic SARS-CoV-2. **c**, Spider curves of body weight changes  
6 of individual mouse plotted separated by group. **d**, Mean +/- SEM curves of body weight changes. (Clone 2, n  
7 = 8; Clone 6, n = 7, and DPBS, n = 8). **e**, Survival curves of antibody and placebo (DPBS) treated hACE2  
8 transgenic mice under lethal challenges of authentic SARS-CoV-2 (the same experiment in **c-d**).

9 Therapeutic efficacy testing.

10 **f-h**, Body weight curves of antibody and placebo (isotype hIgG1) treated hACE2 transgenic mice under lethal  
11 challenges of authentic SARS-CoV-2. **f**, Spider curves of body weight changes of individual mouse plotted  
12 separated by group. **g**, Mean +/- SEM curves of body weight changes. (Clone 2, n = 5; Clone 6, n = 5, and  
13 hIgG1, n = 5). **h**, Survival curves of antibody and placebo (hIgG1) treated hACE2 transgenic mice under lethal  
14 challenges of authentic SARS-CoV-2 (the same experiment in **f-g**).

15 In this figure:

16 Data are shown as mean  $\pm$  s.e.m. plus individual data points in dot plots.

17 Statistics: Two-way ANOVA was used to assess statistical significance for multi-group curve comparisons;  
18 Log-Rank test was used to assess statistical significance for survival curve comparisons; unless otherwise  
19 noted. The p-values are indicated in the plots.

20 Source data and additional statistics for experiments are provided in a supplemental excel file.

21

22 **Figure 6 | Generation, biophysical characterization, and functional testing of a humanized mAb clone**

23 **a**, Schematics of antibody humanization.

24 **b**, SDS-PAGE of purified antibodies of humanized clone (Clone 13A) along with other clones.

25 **c**, Octet measurement of Clone 13A using the BLI assay.

26 **d**, (Top) Neutralization assay on Clone 2 and a Clone 13A (humanized Clone 2) using WT SARS-CoV-2 Spike  
27 pseudotyped HIV-lentivirus carrying an EGFP reporter. (Bottom) Neutralization assay on Clone 2 and a Clone  
28 13A (humanized Clone 2) using B.1.617 variant SARS-CoV-2 Spike pseudotyped HIV-lentivirus carrying an  
29 EGFP reporter.

30 **d**, *In vitro* neutralization of top mAb clones (Clones 2, 6, 13A) along with representative therapeutic antibody  
31 clones (RGEN 10933, 10987) against authentic SARS-CoV-2 WA1/2020 and B.1.617.2 (Delta) viruses in  
32 BL3 setting.

SARS-CoV-2 mAbs and CryoEM structures

1 **f-g**, Body weight curves of humanized antibody Clone 13A and placebo (isotype hIgG1) treated hACE2  
2 transgenic mice under lethal challenges of authentic SARS-CoV-2 WA1. **f**, Spider curves of body weight  
3 changes of individual mouse plotted separated by group. **g**, Mean +/- SEM curves of body weight changes.  
4 (Clone 13A, n = 9, and hIgG1, n = 8).  
5 **h**, Survival curves of Clone 13A antibody and placebo (hIgG1) treated hACE2 transgenic mice under lethal  
6 challenges of authentic SARS-CoV-2 (the same experiment in **f-g**).  
7 **i-j**, Body weight curves of humanized antibody Clone 13A and placebo (isotype hIgG1) treated hACE2  
8 transgenic mice under lethal challenges of authentic SARS-CoV-2 Delta. **i**, Spider curves of body weight  
9 changes of individual mouse plotted separated by group. **j**, Mean +/- SEM curves of body weight changes.  
10 (Clone 13A, n = 8, and hIgG1, n = 8).

11 In this figure:

12 Data are shown as mean  $\pm$  s.e.m. plus individual data points in dot plots.

13 Statistics: Two-way ANOVA was used to assess statistical significance for multi-group curve comparisons;  
14 Log-Rank test was used to assess statistical significance for survival curve comparisons; unless otherwise  
15 noted. The p-values are indicated in the plots.

16 Source data and additional statistics for experiments are provided in a supplemental excel file.

17

18

19 **Extended Data Figure Legends**

20 **Extended Data Figure 1 | Measurement of mouse serum titers in SARS-CoV-2 Spike RBD immunized  
21 mice in this study.**

22 **a**, Schematic of experiments. This schematic illustrates neutralizing antibody identification process through  
23 RBD-his tag protein mouse immunization-single B cell sequencing (**Top**), along with main assays of  
24 downstream analyses (**Middle**). The paired heavy chain and light chain sequences of the B cells were obtained  
25 using 10X Genomics VDJ sequencing. Antibodies were reconstructed by cloning of IgG heavy and light chains  
26 into human IgG1 backbone and expressed as recombinant monospecific or bispecific mAbs. Lead antibody  
27 clones were subjected to characterizations including neutralization assays, BL3 level anti- authentic SARS-  
28 CoV-2 efficacy testing, and structural analyses by Cryo-EM. (**Bottom**) A timeline of mouse immunization for  
29 antibody development.

30 **b**, SARS-CoV-2 RBD reactivity ELISA result of serum samples from different RBD immunized C57BL/6J  
31 (b) and BALB/c (c) mice.

32 **c**, SARS-CoV-2 RBD reactivity ELISA result of recombinant monospecific mAb clones identified from single  
33 BCR sequencing of RBD immunized C57BL/6J (top) and BALB/c (bottom) mice.

1 **d**, Schematics of construct design and antibody structure of bispecific antibodies used in this study.  
2 **e**, SARS-CoV-2 RBD reactivity ELISA result of top monospecific mAb clones (Clones 2 and 6) and a  
3 bispecific mAb clone (Clone 16).

4 Source data and additional statistics for experiments are provided in a supplemental excel file.  
5

6 **Extended Data Figure 2 | Neutralization capability testing of antibody clones with HIV1-based and VSV-  
7 G-based WT SARS-CoV-2 spike pseudotyped virus.**

8 **a**, Neutralization assay on Clone 2, and Clone 3 using WT SARS-CoV-2 Spike pseudotyped lentivirus carrying  
9 a luciferase reporter.

10 **b**, Neutralization assay on Clone 2, Clone 6, Clone 5 and Clone 11 using WT SARS-CoV-2 Spike pseudotyped  
11 VSV- virus carrying a luciferase reporter.

12 **c**, Neutralization assay on Clone 2, Clone 5, Clone 6, Clone 12 and Clone 13, using WT SARS-CoV-2 Spike  
13 pseudotyped HIV-lentivirus carrying a luciferase reporter.

14 **d**, Cell fusion assay with SARS-CoV-2 Spike on top mAb clones.

15 **e**, Cell fusion assay with SARS-CoV-2 UK variant Spike on top mAb clones

16 Source data and additional statistics for experiments are provided in a supplemental excel file.  
17

18 **Extended Data Figure 3 | Cryo-EM density maps of the ectodomain of SARS-CoV-2 S trimer (gray) in  
19 complexes with Clone 2 (a) or Clone 6 (b) Fabs (green, yellow and cyan).**

20 **Extended Data Figure 4 | Additional binding interfaces between spike RBD and both clone Fabs.**

21 **a**, Overlay of a down-RBD-bound Clone 2 Fab (cyan ribbons with transparent surface) onto a down-RBD-  
22 bound Clone 6 Fab (cyan surface) reveals a steric clash between the Clone 2 Fab and a neighboring RBD.

23 **b**, The additional binding interface between a down-RBD-binding Clone 2 Fab and an adjacent up-RBD in S  
24 trimers with 2 RBDs up.

25 **c**, The down-RBD-binding Clone 6 Fab sits on top of two adjacent down-RBDs in S trimers with 2 or 3 RBDs  
26 down. The CDRL1 loop highlighted in red inserts between two adjacent RBDs.

27 **d**, The additional binding interfaces between a down-RBD-binding Fab and adjacent down- or up-RBD in all  
28 Clone 6 Fab-S trimer complexes. The residues involved in the interactions are highlighted in red.

29 **e**, ACE2 bound to an up-RBD has additional steric clashes with a neighboring down-RBD bound Clone 2 (left)  
30 or Clone 6 (right) Fab in spike trimers with either 1 RBD up or 2 RBDs up. ACE2 is shown as light gray  
31 surface, Clone 2 and 6 Fabs are shown as yellow (on down-RBD) or green (on up-RBD) ribbons, and RBDs  
32 are shown as gray surfaces.

1

2 **Extended Data Figure 5 | Detailed atomic interactions at the spike RBD-Fab interfaces.**

3 **a**, Cryo-EM maps of the spike RBD binding interfaces with the Clone 2 Fab CDRH loops (upper panel) and  
4 CDRL loops (lower panel), with the fitted models in ribbon representation. The key interactions and  
5 electrostatic surfaces (blue, positively charged; red, negatively charged) at the binding interfaces are shown in  
6 respective insets.

7 **b**, Cryo-EM maps of the spike RBD binding interfaces with the Clone 6 Fab CDRH loops (upper panel) and  
8 CDRL loops (lower panel), with the fitted models in ribbon representation. The key interactions are shown in  
9 respective insets.

10

11 **Extended Data Figure 6 | Comparison of binding orientations between Clone 2/6 and previous reported**  
12 **antibodies on SARS-CoV-2 spike RBD, with the RBD portions overlaid.** **a**, Three previously reported  
13 antibodies bind the spike RBD in overall similar orientations as those of Clone 2/6, but with substantial  
14 rotations or shifts. **b**, Two previous reported antibodies resemble the binding conformations of Clone 2/6 on  
15 spike RBD, however with the positions of heavy chains and light chains swapped. The PDB IDs of the  
16 published Fab-RBD structures: 2H2, 7DK5; CV05-163, 7LOP; S2H13, 7JV4; CT-P59, 7CM4; BD23, 7BYR.

17

18 **Extended Data Figure 7 | Local resolution estimations of the cryo-EM maps of SARS-CoV-2 S**  
19 **ectodomain trimer (gray) in complexes with Clone 2 (a) or Clone 6 (b) Fabs.** Fourier shell correlation  
20 (FSC) curves of the half-maps of each complex structure from gold standard refinement calculated by  
21 cryoSPARC are also shown, respectively.

22

23 **Extended Data Figure 8 | Epitope and mutation analysis of the Fab-spike RBD interfaces for lead mAb**  
24 **clone in comparison with representative existing clinical antibodies**

25 Structural comparison of Clone 2, REGN 10933 and REGN 10987 revealed their distinct RBD epitopes and  
26 varied susceptibility to mutations of Delta variant. RBD structural model of Delta in complex with REGN  
27 10987 (A, Pink, PDB: 6XDG), REGN 10933 (B, Pink, PDB: 6XDG) and Clone 2 (Cyan) is shown.

28 **a**, The epitope of REGN 10987 are mainly distributed in the left shoulder loop 1 (blue) region, which extends  
29 to L452R mutation site, while the clone 2 mainly targets the right ridge of RBD.

30 **b**, The paratopes of REGN 10933 and clones targeting the E484Q of RBD are labeled and shown. The  
31 remaining parts of the antibody structures were set 50% transparent.

32 **c**, Overlay of structures of REGN 10933, REGN 10987 and Clone 2 Fab with RBD, with analysis of  
33 representative key residues.

1

2

3 **Supplemental Datasets**

4 **Dataset S1 Single cell BCR sequencing processed data**

5

6 **Supplemental Source Data and Statistics**

7 Original data and statistics for non-high-throughput data used in figure generation.

8 “**CoVmAbBis\_Statistics\_Original\_data\_v7.xlsx**”

9

1      **References**

2

3      1      Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* **20**, 533-534, doi:10.1016/S1473-3099(20)30120-1 (2020).

4

5      2      Hacisuleyman, E. *et al.* Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* **384**, 2212-2218, doi:10.1056/NEJMoa2105000 (2021).

6

7      3      Taylor, P. C. *et al.* Neutralizing monoclonal antibodies for treatment of COVID-19. *Nat Rev Immunol*, doi:10.1038/s41577-021-00542-x (2021).

8

9      4      Liu, Z. *et al.* Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe* **29**, 477-488.e474, doi:10.1016/j.chom.2021.01.014 (2021).

10

11      5      Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* **372**, doi:10.1126/science.abg3055 (2021).

12

13      6      Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell*, doi:10.1016/j.cell.2021.02.037 (2021).

14

15      7      Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*, doi:10.1038/s41586-021-03398-2 (2021).

16

17      8      Tegally, H. *et al.* Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**, 438-443, doi:10.1038/s41586-021-03402-9 (2021).

18

19      9      Rambaut, A. *et al.* Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* **6**, 415, doi:10.1038/s41564-021-00872-5 (2021).

20

21      10      Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* **5**, 1403-1407, doi:10.1038/s41564-020-0770-5 (2020).

22

23      11      Yadav, P. D. *et al.* Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *Clin Infect Dis*, doi:10.1093/cid/ciab411 (2021).

24

25      12      Planas, D. *et al.* Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. *bioRxiv*, 2021.2005.2026.445838, doi:10.1101/2021.05.26.445838 (2021).

26

27      13      Wall, E. C. *et al.* Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet*, doi:10.1016/S0140-6736(21)01290-3 (2021).

28

29

30      14      Tada, T. *et al.* The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. *bioRxiv* <https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1.full.pdf>, doi:<https://doi.org/10.1101/2021.05.14.444076> (2021).

31

32      15      Singh, J., Rahman, S. A., Ehtesham, N. Z., Hira, S. & Hasnain, S. E. SARS-CoV-2 variants of concern are emerging in India. *Nature Medicine*, doi:10.1038/s41591-021-01397-4 (2021).

33

34

35

36

1 16 Thangaraj, J. W. V. *et al.* Predominance of delta variant among the COVID-19 vaccinated and  
2 unvaccinated individuals, India, May 2021. *J Infect*, S0163-4453(0121)00387-X,  
3 doi:10.1016/j.jinf.2021.08.006 (2021).

4 17 O'Dowd, A. Covid-19: Cases of delta variant rise by 79%, but rate of growth slows. *BMJ* **373**, n1596,  
5 doi:10.1136/bmj.n1596 (2021).

6 18 Alexandar, S., Ravisankar, M., Kumar, R. S. & Jakkan, K. A comprehensive review on Covid-19  
7 Delta variant. *International Journal of Pharmacology and Clinical Research (IJPGR)* **5**, 83-85  
8 (2021).

9 19 Wilhelm, A. *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and  
10 monoclonal antibodies. *medRxiv*, 2021.2012.2007.21267432, doi:10.1101/2021.12.07.21267432  
11 (2021).

12 20 Kannan, S. R. *et al.* Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing  
13 antibodies. *Journal of Autoimmunity* **126**, 102779, doi:<https://doi.org/10.1016/j.jaut.2021.102779>  
14 (2022).

15 21 Bai, Y. *et al.* International risk of SARS-CoV-2 Omicron variant importations originating in South  
16 Africa. *medRxiv*, 2021.2012.2007.21267410, doi:10.1101/2021.12.07.21267410 (2021).

17 22 Parray, H. A. *et al.* Hybridoma technology a versatile method for isolation of monoclonal antibodies,  
18 its applicability across species, limitations, advancement and future perspectives. *Int  
19 Immunopharmacol* **85**, 106639-106639, doi:10.1016/j.intimp.2020.106639 (2020).

20 23 Horns, F., Dekker, C. L. & Quake, S. R. Memory B Cell Activation, Broad Anti-influenza  
21 Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics. *Cell Rep* **30**, 905-  
22 913 e906, doi:10.1016/j.celrep.2019.12.063 (2020).

23 24 Goldstein, L. D. *et al.* Massively parallel single-cell B-cell receptor sequencing enables rapid  
24 discovery of diverse antigen-reactive antibodies. *Commun Biol* **2**, 304, doi:10.1038/s42003-019-  
25 0551-y (2019).

26 25 Setliff, I. *et al.* High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell*  
27 **179**, 1636-1646 e1615, doi:10.1016/j.cell.2019.11.003 (2019).

28 26 Corti, D. *et al.* Protective monotherapy against lethal Ebola virus infection by a potently neutralizing  
29 antibody. *Science* **351**, 1339-1342, doi:10.1126/science.aad5224 (2016).

30 27 Cao, Y. *et al.* Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput  
31 Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **182**, 73-84.e16,  
32 doi:<https://doi.org/10.1016/j.cell.2020.05.025> (2020).

33 28 Alsoussi, W. B. *et al.* A potently neutralizing antibody protects mice against SARS-CoV-2 infection.  
34 *The Journal of Immunology* **205**, 915-922 (2020).

35 29 Li, F. *et al.* Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel  
36 neutralizing antibody. *Protein Cell* **12**, 751-755, doi:10.1007/s13238-020-00807-6 (2021).

37 30 Belouzard, S., Millet, J. K., Licitra, B. N. & Whittaker, G. R. Mechanisms of coronavirus cell entry  
38 mediated by the viral spike protein. *Viruses* **4**, 1011-1033, doi:10.3390/v4061011 (2012).

SARS-CoV-2 mAbs and CryoEM structures

1 31 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a  
2 Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278, doi:10.1016/j.cell.2020.02.052 (2020).

3 32 Shang, J. *et al.* Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A* **117**, 11727-  
4 11734, doi:10.1073/pnas.2003138117 (2020).

5 33 Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu Rev Virol* **3**, 237-261,  
6 doi:10.1146/annurev-virology-110615-042301 (2016).

7 34 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*  
8 **367**, 1260-1263, doi:10.1126/science.abb2507 (2020).

9 35 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin.  
10 *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).

11 36 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.  
12 *Cell* **181**, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).

13 37 Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2  
14 receptor. *Nature* **581**, 215-220, doi:10.1038/s41586-020-2180-5 (2020).

15 38 Xia, S. *et al.* Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike  
16 protein. *Cell Mol Immunol* **17**, 765-767, doi:10.1038/s41423-020-0374-2 (2020).

17 39 Zhou, T. *et al.* Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-  
18 Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. *Cell Host  
19 Microbe* **28**, 867-879 e865, doi:10.1016/j.chom.2020.11.004 (2020).

20 40 Zost, S. J. *et al.* Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature*  
21 **584**, 443-449, doi:10.1038/s41586-020-2548-6 (2020).

22 41 Liu, L. *et al.* Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*  
23 **584**, 450-456, doi:10.1038/s41586-020-2571-7 (2020).

24 42 Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape  
25 seen with individual antibodies. *Science* **369**, 1014-1018, doi:10.1126/science.abd0831 (2020).

26 43 Wang, C. *et al.* A human monoclonal antibody blocking SARS-CoV-2 infection. *Nature  
27 communications* **11**, 1-6 (2020).

28 44 Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD,  
29 RBD, and S2. *Cell* **184**, 3936-3948.e3910, doi:<https://doi.org/10.1016/j.cell.2021.06.005> (2021).

30 45 Chen, P. *et al.* SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. *New  
31 England Journal of Medicine* **384**, 229-237 (2021).

32 46 Zhang, C. *et al.* Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2  
33 infections. *Nat Commun* **12**, 264, doi:10.1038/s41467-020-20465-w (2021).

34 47 Yuan, M. *et al.* Structural and functional ramifications of antigenic drift in recent SARS-CoV-2  
35 variants. *bioRxiv*, doi:10.1101/2021.02.16.430500 (2021).

1 48 Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike  
2 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024-1042  
3 e1021, doi:10.1016/j.cell.2020.09.037 (2020).

4 49 Kim, C. *et al.* A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2  
5 spike protein. *Nat Commun* **12**, 288, doi:10.1038/s41467-020-20602-5 (2021).

6 50 Cao, Y. *et al.* Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput  
7 Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell* **182**, 73-84 e16,  
8 doi:10.1016/j.cell.2020.05.025 (2020).

9 51 Asarnow, D. *et al.* Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of  
10 syncytia. *Cell* **184**, 3192-3204.e3116, doi:10.1016/j.cell.2021.04.033 (2021).

11 52 McCray, P. B., Jr. *et al.* Lethal infection of K18-hACE2 mice infected with severe acute respiratory  
12 syndrome coronavirus. *J Virol* **81**, 813-821, doi:10.1128/JVI.02012-06 (2007).

13 53 Oladunni, F. S. *et al.* Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting  
14 enzyme 2 transgenic mice. *Nat Commun* **11**, 6122, doi:10.1038/s41467-020-19891-7 (2020).

15 54 Zheng, J. *et al.* COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice.  
16 *Nature* **589**, 603-607, doi:10.1038/s41586-020-2943-z (2021).

17 55 Ke, Z. *et al.* Structures and distributions of SARS-CoV-2 spike proteins on intact virions. *Nature* **588**,  
18 498-502, doi:10.1038/s41586-020-2665-2 (2020).

19 56 Xu, C. *et al.* Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with  
20 receptor ACE2 revealed by cryo-EM. *Sci Adv* **7**, doi:10.1126/sciadv.abe5575 (2021).

21 57 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases  
22 Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827.e819, doi:10.1016/j.cell.2020.06.043 (2020).

23 58 Supasa, P. *et al.* Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine  
24 sera. *Cell* **184**, 2201-2211 e2207, doi:10.1016/j.cell.2021.02.033 (2021).

25 59 Wang, P. *et al.* Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody  
26 Neutralization. *bioRxiv*, doi:10.1101/2021.01.25.428137 (2021).

27 60 Davies, N. G. *et al.* Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.  
28 *Nature*, doi:10.1038/s41586-021-03426-1 (2021).

29 61 Liu, Y. *et al.* Neutralizing Activity of BNT162b2-Elicited Serum. *N Engl J Med*,  
30 doi:10.1056/NEJMc2102017 (2021).

31 62 Conti, P. *et al.* The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a  
32 vaccine problem. *J Biol Regul Homeost Agents* **35**, 1-4, doi:10.23812/21-3-e (2021).

33 63 Chen, R. E. *et al.* In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. *Nature*  
34 **596**, 103-108, doi:10.1038/s41586-021-03720-y (2021).

35 64 Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **593**, 130-  
36 135, doi:10.1038/s41586-021-03398-2 (2021).

1 65 Motozono, C. *et al.* SARS-CoV-2 spike L452R variant evades cellular immunity and increases  
2 infectivity. *Cell Host & Microbe*, doi:10.1016/j.chom.2021.06.006.

3 66 Hansen, J. *et al.* Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody  
4 cocktail. *Science* **369**, 1010-1014, doi:10.1126/science.abd0827 (2020).

5 67 Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644,  
6 doi:10.1038/s41586-021-03207-w (2021).

7 68 Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R. & Suthar, M. S. Neutralizing Antibodies Against  
8 SARS-CoV-2 Variants After Infection and Vaccination. *JAMA* **325**, 1896-1898,  
9 doi:10.1001/jama.2021.4388 (2021).

10 69 Zhu, Y., Li, J. & Pang, Z. Recent insights for the emerging COVID-19: Drug discovery, therapeutic  
11 options and vaccine development. *Asian J Pharm Sci* **16**, 4-23, doi:10.1016/j.ajps.2020.06.001  
12 (2021).

13 70 Schaefer, W. *et al.* Immunoglobulin domain crossover as a generic approach for the production of  
14 bispecific IgG antibodies. *P Natl Acad Sci USA* **108**, 11187-11192, doi:10.1073/pnas.1019002108  
15 (2011).

16 71 Fabian Schmidt, Y. W., Frauke Muecksch, Hans-Heinrich Hoffmann, Eleftherios Michailidis, Julio  
17 C.C. Lorenzi, Pilar Mendoza, Magdalena Rutkowska, Eva Bednarski, Christian Gaebler, Marianna  
18 Agudelo, Alice Cho, Zijun Wang, Anna Gazumyan, Melissa Cipolla, Marina Caskey, Davide F.  
19 Robbiani, Michel C. Nussenzweig, Charles M. Rice, Theodora Hatzioannou, Paul D. Bienasz.  
20 Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J  
21 Exp Med* **217**(11), doi:<https://doi.org/10.1084/jem.20201181> (2020).

22 72 Wei, J. *et al.* Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2  
23 Infection. *Cell* **184**, 76-91 e13, doi:10.1016/j.cell.2020.10.028 (2021).

24 73 VanBlargan, L. A. *et al.* A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern  
25 by utilizing unique binding residues in a highly conserved epitope. *Immunity* **54**, 2399-2416 e2396,  
26 doi:10.1016/j.immuni.2021.08.016 (2021).

27 74 Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen  
28 movements. *J Struct Biol* **152**, 36-51, doi:10.1016/j.jsb.2005.07.007 (2005).

29 75 Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination.  
30 *J Struct Biol* **180**, 519-530, doi:10.1016/j.jsb.2012.09.006 (2012).

31 76 Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron  
32 micrographs. *J Struct Biol* **192**, 216-221, doi:10.1016/j.jsb.2015.08.008 (2015).

33 77 Wagner, T. *et al.* SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-  
34 EM. *Commun Biol* **2**, 218, doi:10.1038/s42003-019-0437-z (2019).

35 78 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid  
36 unsupervised cryo-EM structure determination. *Nat Methods* **14**, 290-296, doi:10.1038/nmeth.4169  
37 (2017).

1 79 Scheres, S. H. & Chen, S. Prevention of overfitting in cryo-EM structure determination. *Nat Methods*  
2 9, 853-854, doi:10.1038/nmeth.2115 (2012).

3 80 Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and  
4 contrast loss in single-particle electron cryomicroscopy. *J Mol Biol* **333**, 721-745,  
5 doi:10.1016/j.jmb.2003.07.013 (2003).

6 81 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and analysis. *J*  
7 *Comput Chem* **25**, 1605-1612, doi:10.1002/jcc.20084 (2004).

8 82 Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein structures and complexes.  
9 *Nucleic Acids Res* **46**, W296-W303, doi:10.1093/nar/gky427 (2018).

10 83 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta*  
11 *Crystallogr D Biol Crystallogr* **66**, 486-501, doi:10.1107/S0907444910007493 (2010).

12 84 Murshudov, G. N. *et al.* REFMAC5 for the refinement of macromolecular crystal structures. *Acta*  
13 *Crystallogr D Biol Crystallogr* **67**, 355-367, doi:10.1107/S0907444911001314 (2011).


14 85 Afonine, P. V. *et al.* Real-space refinement in PHENIX for cryo-EM and crystallography. *Acta*  
15 *Crystallogr D Struct Biol* **74**, 531-544, doi:10.1107/S2059798318006551 (2018).

16 86 Afonine, P. V. *et al.* New tools for the analysis and validation of cryo-EM maps and atomic models.  
17 *Acta Crystallogr D Struct Biol* **74**, 814-840, doi:10.1107/S2059798318009324 (2018).

18

# Figure 1

**a**




**b**

Top BCR pairs of IgG1 clonotypes in C57BL/6J mice						CDR3 <sub>light</sub>	Clonal freq %
Clonotype	V <sub>Heavy</sub>	V <sub>light</sub>	C <sub>Heavy</sub>	CDR3 <sub>Heavy</sub>			
#1	IGHV1-80	IGKV14-111	IGHG1	CARSPDW	CLOYDEFPTWF	3.17%	
#2	IGHV1-42	IGKV3-1	IGHG1	CARSRGDYW	CQQSRKVPWTF	1.61%	
#3	IGHV1-18	IGKV12-46	IGHG1	CARSNDFFDYW	CQHFVGTPTF	1.58%	
#4	IGHV4-1	IGKV1-135	IGHG1	CAIGAYW	CWQGTHFPYTF	1.58%	


  

Top BCR pairs of IgG1 clonotypes in BALB/c_mmBCR						CDR3 <sub>light</sub>	Clonal freq %
Clonotype	V <sub>Heavy</sub>	V <sub>light</sub>	C <sub>Heavy</sub>	CDR3 <sub>Heavy</sub>			
#1	IGHV1-1	IGKV5-37	IGHG1	CARQGYGNYFDYW	CLQGYSTPLTF	0.95%	
#2	IGHV1-4	IGKV3-2	IGHG1	CAREGHVRGPAYW	CQQSKEVPTF	0.85%	
#3	IGHV1-22	IGKV1-135	IGHG1	CARTDYW	CWQGTHFPYTF	0.64%	
#4	IGHV9-1	IGKV1-117	IGHG1	CARPGRDYW	CFQGSHVPWTF	0.64%	
#5	IGHV4-1	IGKV5-37	IGHG1	CARQGYGNYFDYW	CLQGYITPLTF	0.53%	
#6	IGHV9-3	IGKV1-135	IGHG1	CARINGAMDYW	CWQGSTHFPQTF	0.53%	


**c**



**d**



**e**





**Figure 2**

Two RBDs up (281k, 60%)



Three RBDs up (181k, 40%)

**a**

Side view



Top view




**b**

Three RBDs down (66k, 26%)




One RBD up (111k, 43%)


Two RBDs up (81k, 31%)

Side view




Top view




**Figure 3**

## Figure 4


a




b




c




d




e




f



g




## Figure 5




## Figure 6


**a**




**b**



**c**





**d**




**e**


### Authentic virus - WA1/2020




### Authentic virus - Delta




**f**




**g**




**h**



**i**




**j**




# Extended Data Figure 1


**a**





### Timeline of mouse Immunization




**b**




**c**



**d**




**e**




## Extended Data Figure 2


**a**




**b**





**c**




**d**





### WT/WA1 Spike - Cell fusion



**e**



### Alpha Variant Spike - Cell fusion




# Extended Data Figure 3


**a**

Two RBDs up (281k, 60%)



Side view



Three RBDs up (181k, 40%)




Top view




**b**

Three RBDs down (68k, 26%)


Side view






One RBD up (111k, 43%)









Two RBDs up (81k, 31%)




Top view




# Extended Data Figure 4

**a****b****c****d****e**

# Extended Data Figure 5



# Extended Data Figure 6

**a**


90°

Fab2  
Fab6  
2H2




90°

Fab2  
Fab6  
CT-P59  
BD23




90°

Fab2  
Fab6  
CV05-163



90°

90°




90°

Fab2  
Fab6  
S2H13


**b**

90°

Fab2  
Fab6  
CT-P59  
BD23




90°





90°

## Extended Data Figure 7


**a**





Two RBDs up





Three RBDs up





**b**




Three RBDs down



One RBD up




Two RBDs up




## Extended Data Figure 8

**a**



**b**



**c**

